УЗЕЛ ШПРИЦА ДЛЯ ГЕРМЕТИКА

Настоящее изобретение относится к медицинской технике, а именно к медицинскому узлу шприца для герметика. Аспект настоящего изобретения может предоставлять узел шприца для герметика, содержащий: первый шприц, включающий в себя множество камер и выпускающий первый раствор, который представляет собой смесь буферного раствора и порошка соединения; шприц с реакционным раствором, включающий в себя по меньшей мере одну камеру и выпускающий реакционный раствор, способный вступать в реакцию с первым раствором; основание, в котором устойчиво установлены первый шприц и шприц с реакционным раствором; и соединитель для соединения первого шприца и шприца с реакционным раствором для смешивания и выпуска первого раствора и реакционного раствора, причем первый раствор и реакционный раствор реагируют друг с другом, что изменяет их свойства таким образом, что модуль накопления при сдвиге превышает модуль потерь при сдвиге, и первый шприц включает в себя: три уплотнительных элемента, предусмотренных внутри ...

БИОРАЗЛАГАЕМАЯ МЕДИЦИНСКАЯ КЛЕЯЩАЯ ИЛИ ГЕРМЕТИЗИРУЮЩАЯ КОМПОЗИЦИЯ

Изобретение относится к химико-фармацевтической промышленности и представляет собой медицинскую клеящую или заполняющую композицию для склеивания, заполнения, нанесения покрытия, образования раневого покрытия и гемостаза на биологических тканях, включающую: (a) первый компонент, содержащий окисленные гликозаминогликаны, получаемые окислением посредством введения формильной группы; и (b) второй компонент, содержащий полиамин, включающий две или более аминогруппы, причем рН второго компонента в водном растворе составляет от 8,5 до 11,0; в которой окисленный гликозаминогликан выбран из группы, состоящей из окисленной гиалуроновой кислоты, окисленного хондроитинсульфата, окисленного хондроитина, окисленного дерматансульфата и окисленного кератансульфата, и в которой полиамин выбран из группы, состоящей из полилизина, путресцина, кадаверина, спермидина, спермина, протамина и полиэтиленимина (ПЭИ). Изобретение позволяет создать клеящую или заполняющую композицию, пригодную для использования на ...

ГЕМОСТАТИЧЕСКИЕ КОМПОЗИЦИИ

... 1. Гемостатическая композиция, содержащая желатин в форме частиц, подходящей для применения с целью гемостаза, отличающаяся тем, что композиция представлена в форме пасты, содержащей от 15,0 до 19,5 мас. % сшитого желатина, предпочтительно от 16,0 до 19,5 мас. %, от 16,5 до 19,5 мас. %, от 17,0 до 18,5 мас. % или от 17,5 до 18,5 мас. %, более предпочтительно от 16,5 до 19,0 мас. % или от 16,8 до 17,8 мас. %, особенно предпочтительно от 16,5 до 17,5 мас. % и от 0,5 до 5,0 мас. %, предпочтительно от 1,0 до 5,0 мас. %, предпочтительно от 2,0 до 4,5 мас. %, более предпочтительно от 1,5 до 5,0 мас. %, наиболее предпочтительно около 1,5 мас. % вещества, облегчающего ее экструзию, где веществом, облегчающего ее экструзию, является альбумин.2. Гемостатическая композиция по п. 1, в которой сшитым желатином является желатин, сшитый глутаральдегидом, или желатин, сшитый генипином.3. Гемостатическая композиция по п. 2, в которой сшитый желатин является желатином типа В.4. Гемостатическая композиция ...

ПЕРЕКРЫВАЮЩЕЕ КРОВОТОК ТВЕРДОФАЗНОЕ ВЕЩЕСТВО С ПОКРЫТИЕМ ИЗ ИММОБИЛИЗОВАННОГО СВЯЗУЮЩЕГО ВЕЩЕСТВА

... 1. Способ лечения васкуляризированной опухоли или гиперплазированной ткани, заключающийся в том, что млекопитающему-носителю васкуляризированной опухоли или гиперплазированной ткани, вводят твердофазное средство, содержащее связывающее средство, способное связывать тромбоциты, и затем in vivo индуцируют тромб, в ходе осуществления которого: происходит захват тромбоцитов путем их связывания со связывающим средством, иммобилизованным на твердофазном средстве или внутри твердофазного средства, индуцируется активация тромбоцитов, и происходит образование тромба. 2. Способ по п.1, в котором твердофазное средство представляет собой частицы. 3. Способ по п.1, в котором твердофазное средство представляет собой спираль. 4. Способ по п.1, в котором твердофазное средство представляет собой стент. 5. Способ по п.1, в котором связывающее тромбоциты средство представляет собой рекомбинантный фактор фон Виллебранда. 6. Способ по п.1, в котором связывающее тромбоциты средство представляет собой фактор ...

WACHSTUMSFAKTOR ENTHALTENDE MATRIX ZUR BEHANDLUNG VON KNORPELSCHÄDEN.

System zur Behandlung von Aneurysmen

Haemostatic wound dressing

SEPARATION OF THROMBOZYTEN FROM FULL BLOOD FOR USE AS WUNDHEILMITTEL

INJECT-CASH FIBRIN COMPOSITION FOR BONE REINFORCEMENT

ENRICHED PLASMA DERIVATIVE FOR THE SUPPORT OF WUNDVERSCHLUSS AND WUNDABDECKUNG.

PREPARATIONS AND PROCEDURES FOR THE TREATMENT OF BLEEDING DISTURBANCES.

ENRICHED PLASMA DERIVATIVE FOR THE SUPPORT OF WUNDVERSCHLUSS AND CICATRISATION.

Cerebrospinal fluid leakage occlusion

Methods and materials for treating a cerebrospinal fluid leakage are described herein. One method for treating cerebrospinal fluid leakage includes occluding cerebrospinal fluid leakage by administering an effective amount of a self-assembling peptide solution to a target area of a cerebrospinal fluid leakage, where the self-assembling peptide is between 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions.

BLEEDING DISORDERS TREATED WITH FACTOR VIIA

Process of making flowable hemostatic compositions and devices containing such compositions

SEALANT OR TISSUE GENERATING PRODUCT

METHOD AND KIT PROVIDING BIOADHESIVE BINDING OR COATING WITH POLYPHENOLIC MUSSEL PROTEINS

Tissue adhesives and sealants and method for their use

TISSUE ADHESIVES AND SEALANTS AND METHOD FOR THEIR Abstract Compositions provided by mixing a biotin-containing component and an avidin containing component are useful as an adhesive or sealant for medical/surgical uses.

Compositions and therapeutic methods using morphogenic proteins and stimulatory factors

Compositions and therapeutic methods using morphogenic proteins and stimulatory factors

CALCIUM PHOSPHATE DELIVERY VEHICLES FOR OSTEOINDUCTIVE PROTEINS

A composition for treating a mammal having a bone defect. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed.

PHOTOACTIVATED CROSSLINKING OF A PROTEIN OR PEPTIDE

A method of crosslinking a protein or peptide for use as a biomaterial, the method comprising the step of irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a crosslinking reaction to form a 3-dimensional matrix of the biomaterial.

THROMBIN PREPARATIONS AND PROCESS FOR THEIR PRODUCTION

... ▓▓▓▓The production of a thrombin preparation which is obtained from prothrombin ▓which▓is, after activation to thrombin without the addition of thromboplastin, ▓purified by a▓hydrophobic interaction chromatography, it being possible subsequently also to▓inactivate or remove viruses, is described. Before or after the hydrophobic ▓interaction▓chromatography it is also possible in addition to carry out a cation exchange▓chromatography. A thrombin preparation which contains as stabilizer a ▓noncovalently▓binding inhibitor and to which further stabilizers can be added for ▓stabilization in the▓liquid state is additionally described.▓ ...

RECOMBINANT SOLUBLE HUMAN TISSUE FACTOR, METHOD OF ITS PRODUCTION AND USES THEREOF

The present invention relates to a novel recombinant soluble human Tissue Factor(RshTF), which is an extrinsic hemostasis factor, produced in human HEK-cells. The present invention also relates to a hitherto unknown method of producing the RshTF as well as specific uses of RshTF and protein compositions comprising RshTF.

SPRAY-DRIED THROMBIN AND METHODS OF USING AND MAKING SPRAY-DRIED THROMBIN

Spray-dried thrombin materials obtained from feedstock solutions comprising less than 5% by weight albumin and excluding trehalose or other excipients as well as methods of manufacturing the thrombin materials and methods of treating bleeding wounds are disclosed. The methods of use include applying reconstituted spray-dried thrombin topically to a bleeding site, optionally in conjunction with gelatin.

MATRIX PROTEIN COMPOSITIONS FOR WOUND HEALING

Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection of inflammation ...

CALCIUM PHOSPHATE DELIVERY VEHICLES FOR OSTEOINDUCTIVE PROTEINS

A composition for treating a mammal having a bone defect. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed.

GROWTH FACTOR CONTAINING MATRIX FOR THE TREATMENT OF CARTILAGE LESIONS

Methods and compositions are provided for the treatment and repair of defects or lesions in the cartilage of humans and other animals. The defect or lesion in the cartilage may be first treated with an enzyme to remove proteoglycans from the defect area. To induce cartilage formation, the defect is filled or otherwise dressed with a biodegradable matrix having pores sufficiently large to allow repair cells to populate the matrix. The matrix filling the defect contains a proliferation agent at a concentration sufficient to stimulate proliferation of repair cells and a transforming factor in an appropriate delivery system to release the transforming factor at a concentration sufficient to transform repair cells in the matrix and defect area into cartilage-producing chondrocytes. The matrix may also contain a chemotactic agent to attract repair cells. The entire treatment may be carried out in a single arthroscopic or open surgical procedure.

HEMOSTATIC COMPOSITION FOR LOCAL HEMOSTASIS

... 2121028 9306855 PCTABS00021 Method for arresting local bleedings by topical use of FVIIa and a hemostatic composition containing FVIIa together with a biologically compatible carrier which permits said FVIIa to remain in contact with said bleeding wound.

METHODS AND COMPOSITIONS FOR SEALING AND ADHERING BIOLOGICAL TISSUES AND MEDICAL USES THEREOF

Compositions and methods for sealing, coating and adhering tissues are provided that utilize a polymeric system comprising at least a Polymer and a crosslinking agent; and, optionally, (i) a Gelation Disrupting Agent, (ii) an Augmentative Polymer or Monomer, (iii) an Adjunct Compound (iv) an Antimicrobial Agent (v) an Adhesion Enhancer, (vi) a Crosslink Augmentating Agent or any combination thereof. Additionally, a Therapeutic Agent may be incorporated.

INJECTABLE FIBRIN COMPOSITION FOR BONE AUGMENTATION

The present invention relates to a biodegradable injectable composition for bone augmentation comprising fibrin, a contrast agent and calcium salt-containing particles, as well as a method for bone augmentation in a patient suffering from a bone disorder comprising injecting said composition into a non-mineralized or hollow portion of said bone.

Method and apparatus to control the heterogeneous flow of bone cement and improve osseointegration of cemented implant

The present invention provides processes for combined applications of making grooves on an implant surface, applying MgO nanoparticles with PMMA cement, restricting the cement movement by PCL nanofiber and tethering biomolecules with PCL nanofiber to enhance mechanical stability and osseointegration of PMMA cement with bone. This is achieved through enhanced osteoconductive properties, roughness, and less viable fracture originating sites at the bone-cement interface. Such combined applications of nanoparticle and nanofiber on the mechanical stability and osseointegration of cemented implant is heretofore unknown, but as provided by the present invention can solve the debonding problem of cemented implant from bone.

Enriched plasma derivative for promoting wound sealing and wound healing

Enriched plasma deriv. (A) comprises components exclusively in powdered form and its compsn. is chosen with regard (a) to optimal activation of exogenous and/or endogenous blood coagulation systems and (b) to a number of physiological and opt. pathological considerations. The major components are fibrinogen (I), thrombin (II), components of the prothrombin (III) complex and protease inhibitors. It may also contain thrombocyte extracts, antibiotics, etc. A pref. formulation contains 60-96 wt.% (I), practically free of water-insoluble globulins (content pref. below 2 wt.%); 0.05-5 wt.% fibrinolysis inhibitors; 0.1-15 wt.% (II) and/or (III). All components are in solid, powdered forms and are simply mixed together. (A) is a biochemical substrate for accelerating haemostasis and optimal regulation of wound closure. It has an almost unlimited storage life at room temp. without agglomeration; can be used directly without any additives, and is quickly soluble in body fluids.

REACTIVE HYDROGEL FORMING FORMULATIONS AND RELATED METHODS

КОМПОЗИЦИИ САМООРГАНИЗУЮЩИХСЯ ПЕПТИДОВ

HOMOGEN BESCHICHTETE VORRICHTUNG MIT OSTEOINDUKTIVEN UND OSTEOKONDUKTIVEN EIGENSCHAFTEN

COMPOSITIONS USING MORPHOGENEN PROTEINS AND STIMULATION FACTORS

PROCEDURE AND SET FOR THE BIOADHÄSIVE CONNECTION OR COATING WITH POLYPHENOLI SHELL PROTEINS

OSTEOINDUKTIVE BIOLOGICAL MATERIALS

GROWTH FACTOR CONTAINING MATRIX FOR THE TREATMENT OF CARTILAGE DAMAGE.

COMPOSITIONS FOR TREATMENT AND RE-ESTABLISHMENT OF CARTILAGE DEFECTS WITH FUNCTIONAL BARRIER LAYER

MATRIX PROTEIN CONTAINING COMPOSITIONS TO THE CICATRISATION

Methods of repairing longitudinal bone defects

Functionalized surgical adhesives

A bioadherent composition includes a first mixture containing a plurality of reactive members of a specific binding pair, said reactive members being bound to a ligand capable of binding a receptor on biological tissue, and a second mixture containing a plurality of complementary reactive members of the specific binding pair, said complementary reactive members being bound to a ligand capable of binding a receptor on biological tissue, said reactive members capable of forming covalent bonds with said complementary reactive members via a reaction selected from Huisgen cycloaddition reactions, Diels-Alder reactions, and/or thiol-alkene reactions. A method for bonding biological tissue involves utilizing the bioadherent composition.

Methods and compositions for sealing tissue leaks

DEVICE HAVING OSTEOINDUCTIVE AND OSTEOCONDUCTIVE PROPERTIES

Process of making flowable hemostatic compositions and devices containing such compositions

The present invention provides a method of making flowable hemostatic compositions and medical devices containing such compositions. 'A' p-f N ...

Biodegradable medical adhesive or sealant composition

The present invention provides a biodegradable medical adhesive or a sealant composition containing an oxidized glycosaminoglycan and a polyamine. The composition of the present invention exhibits improved effects in biodegradation, coating property, gelation time, hemostatic capacity, adhesive force, moisture absorptive capacity and the like, and thus can be applied to various medical uses in which a medical adhesive or sealant can be used, such as biotissue adhesion, filling, coating, adhesion prevention, wound coating, leakage prevention and hemostasis.

Hemostatic compositions

The invention discloses a hemostatic composition comprising crosslinked gelatin in particulate form suitable for use in hemostasis, wherein the composition is present in paste form containing 15.0 to 19.5% (w/w), preferably 16.0 to 19.5% (w/w), 16.5 to 19.5% (w/w), 7.0 to 18.5% (w/w)or 17.5 to 18.5% (w/w),more preferred 16.5 to 19.0% (w/w)or16.8 to 7.8% (w/w), especially preferred 16.5 to 17.5% (w/w), and wherein the composition comprises an extrusion enhancer.

OSTEOINDUCTIVE BIOMATERIALS

In a method of isolating osteogenic protein from bone, in which an osteogenic protein containing fraction is extracted from bone and enriched by a sequence of enrichment steps selected from ultrafiltration and chromatography, the invention provides the improvement of removing higher molecular weight components from the osteogenic protein containing fraction prior to the enrichment steps. The higher molecular weight components have a molecular weight of about 100 - 300 kDa and are selected from collagen, collagen fragments, collagen aggregates and mixtures thereof.

PHARMACEUTICALLY STABLE HEMOSTATIC COMPOSITIONS

It is intended to provide novel hemostatic compositions or hemostatic preparations. Pharmaceutically stable hemostatic compositions in the form of a solution characterized by containing activated blood coagulation factor VII (FVIIa) and blood coagulation factor X (FX) mixed together in a single container. The pH value of the mixture solution ranges from 5.0 to 6.5.

HEMOSTATIC COMPOSITIONS CONTAINING STERILE THROMBIN

... ²²²The present invention includes sterilized hemostatic compositions that contain ²a continuous, biocompatible liquid phase having a solid phase of particles of ²a biocompatible polymer suitable for use in hemostasis and that is ²substantially insoluble in the liquid phase, and sterile thrombin, each of ²which is substantially homogenously dispersed throughout the continuous liquid ²phase, and methods for making such compositions.² ...

BIOACTIVE MATERIALS, METHODS OF MAKING BIOACTIVE MATERIALS AND METHOD OF USE THEREOF

A bioactive material is made using fibroin solutions and suspensions that can be used alone or as a composite with particles such as core/shell particles. The material is designed to support the constructions, repair, regeneration or augmentation of bone and other tissues of the body. The solutions and suspensions can be loaded with core/shell-type particles comprising inorganic core materials that are coated with biodegradable polymers with an outer coating of a calcium phosphate precursor. The fibroin solutions, suspensions, and composites can be injected to fill cavities or to replace missing tissue. After injection, the materials can produce a scaffold capable of promoting tissue regeneration while degrading. The degradation of the particles, when present, can generate additional porosity within the scaffold and release other compounds in a controlled manner to enhance growth and activation of the cells necessary for tissue repair. The ability to inject the fibroin solutions, suspensions ...

PHARMACEUTICALLY STABLE HEMOSTATIC COMPOSITIONS

The present invention is directed to a novel hemostatic composition and a hemostatic pharmaceutical preparation. A pharmaceutically stable hemostatic liquid composition comprising a mixed solution of activated blood coagulation factor VII (FVIIa) and blood coagulation factor X (FX) in a single container. The mixed solution is maintained at pH ranging from 5.0 to 6.5.

PROCESS OF MAKING FLOWABLE HEMOSTATIC COMPOSITIONS AND DEVICES CONTAINING SUCH COMPOSITIONS

... ²²²The present invention is directed to processes of making flowable hemostatic ²compositions and devices that include the flowable hemostatic composition ²disposed therein, where a volume of biocompatible liquid, a volume of a ²biocompatible gas, and an amount of solid particles of a biocompatible polymer ²are mixed together to form a substantially homogenous composition including a ²discontinuous gas phase and the solid particles substantially homogenously ²dispersed throughout a continuous liquid phase to form a flowable hemostatic ²composition, and the composition then transferred into a device suitable for ²applying the flowable hemostatic composition to a site of a body requiring ²hemostasis under conditions effective to maintain the substantially homogenous ²dispersion of the gas phase and the solid particles throughout the liquid ²phase.² ...

DEVICE HAVING OSTEOINDUCTIVE AND OSTEOCONDUCTIVE PROPERTIES

The present invention relates to a device having osteoinductive and osteoconductive properties in vivo comprising a carrier containing calcium phosphate and an osteoinductive protein, wherein said carrier is homogenously coated with said protein. Moreover, the present invention relates to a method for the production of a device having osteoinductive and osteoconductive properties in vivo. The invention encompasses a pharmaceutical composition comprising the device of the invention or a device which is obtainable by the method of the invention and relates to the use of said device for the preparation of a pharmaceutical composition to be used for bone augmentation, for treating bone defects, for treating degenerative and traumatic disc disease, for treating bone dehiscence or to be used for sinus floor elevation. Finally, the invention relates to a kit comprising the device of the invention or a device which is obtainable by the method of the invention.

HEMOSTATIC COMPOSITIONS AND METHODS OF MAKING THEREOF

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.

FUNCTIONALIZED SURGICAL ADHESIVES

A bioadherent composition includes a first mixture containing a plurality of reactive members of a specific binding pair, said reactive members being bound to a ligand capable of binding a receptor on biological tissue, and a second mixture con-taining a plurality of complementary reactive members of the specific binding pair, said complementary reactive members being bound to a ligand capable of binding a receptor on biological tissue, said reactive members capable of forming covalent bonds with said complementary reactive members via a reaction selected from Huisgen cycloaddition reactions, Diels-Alder reactions, and/or thiol-alkene reactions. A method for bonding biological tissue involves utilizing the bioadherent composition.

SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS

Compositions, methods and delivery devices (e.g., pre-filled syringes) for controlling bleeding during surgical procedures are provided, wherein the compositions are characterized as having an aqueous formulation that is capable of adopting a gelled state upon contact with bodily fluids and/or blood of a patient (i.e., physiological conditions).

COMPOSITIONS AND THERAPEUTIC METHODS USING MORPHOGENIC PROTEINS AND STIMULATORY FACTORS

The present invention provides pharmaceutical compositions comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the 13MP protein family. Methods for improving the tissue inductive activity of a morphogenic protein in a mammal using those compositions are provided. This invention also provides implantable morphogenic devices comprising a morphogenic protein and a MPSF disposed within a carrier that are capable of inducing tissue formation in allogeneic and xenogeneic implants. Methods for inducing local tissue formation from a progenitor cell in a mammal using those devices are also provided. A method for accelerating allograft repair in a mammal using morphogenic devices is provided. This invention also provides a prosthetic device comprising a prosthesis coated with a morphogenic protein and a MPSF, and a method for promoting in vivo integration of an implantable prosthetic device ...

presses the hemoglutination peptide and its derivatives and their use

Thrombin preparations and process for their production

Spray-dried thrombin Use and production of spray-dried thrombin and spray-dried thrombin

Modified mussel proteins, their use and related compounds

Hydrogel formulation based microneedle adhesive patch

syringe assembly sealant

Hemostatic compositions

The invention discloses a hemostatic composition comprising crosslinked gelatin in particulate form suitable for use in hemostasis, wherein the composition is present in paste form containing 15.0 to 19.5% (w/w), preferably 16.0 to 19.5% (w/w), 16.5 to 19.5% (w/w), 17.0 to 18.5% (w/w) or 17.5 to 18.5% (w/w), more preferred 16.5 to 19.0% (w/w) or 16.8 to 17.8% (w/w), especially preferred 16.5 to 17.5% (w/w), and wherein the composition comprises an extrusion enhancer.

HEMOSTATIC MATERIAL CONTAINING SYNTHETIC PEPTIDES OR POLYSACCHARIDES

The invention relates to a biodegradable material for hemostasis or sealing during surgery. Said material contains at least one biodegradable carrier material and at least one synthetic adhesive material based on peptides or polysaccharides.

Compositions and therapeutic methods using morphogenic proteins and stimulatory factors

The present invention provides pharmaceutical compositions comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the BMP protein family. Methods for improving the tissue inductive activity of a morphogenic protein in a mammal using those compositions are provided. This invention also provides implantable morphogenic devices comprising a morphogenic protein and a MPSF disposed within a carrier, that are capable of inducing tissue formation in allogeneic and xenogeneic implants. Methods for inducing local tissue formation from a progenitor cell in a mammal using those devices are also provided. A method for accelerating allograft repair in a mammal using morphogenic devices is provided. This invention also provides a prosthetic device comprising a prosthesis coated with a morphogenic protein and a MPSF, and a method for promoting in vivo integration of an implantable prosthetic device ...

Photoactivated crosslinking of a protein or peptide

A method of crosslinking a protein or peptide for use as a biomaterial, the method comprising the step of irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a cross-linking reaction to form a 3-dimensional matrix of the biomaterial.

Self-assembling peptide compositions

The present disclosure provides peptide compositions (e.g., of self-assembling peptides) with particular attributes (e.g., peptide identity, peptide concentration, pH, ionic strength [including salt identity and/or concentration), etc. that show particularly useful material properties. The present disclosure also provides technologies for selecting and/or formulating particular peptide compositions useful in specific contexts. In some embodiments, provided peptide compositions have an elevated pH within the range of about 2.5 to about 3.5 and/or an ionic strength that is above that of a corresponding composition of the same peptide, at the same concentration, in water, but is below a critical salt point for the peptide (e.g., so that the composition is not cloudy).

VASCULAR OCCLUSION SOLID-PHASE AGENT WITH IMMOBILISED PLATELET BINDING AGENT

The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent, causing vessel occlusion.

PHARMACEUTICALLY STABLE HEMOSTATIC COMPOSITIONS

A novel hemostatic composition and a hemostatic pharmaceutical preparation are provided. A pharmaceutically stable hemostatic liquid composition comprising a mixed solution of activated blood coagulation factor VII (FVIIa) and blood coagulation factor X (FX) in a single container. The mixed solution is maintained at pH ranging from 5.0 to 6.5.

HEMOSTATIC COMPOSITION FOR LOCAL HEMOSTASIS

Method for arresting local bleedings by topical use of FVIIa and a hemostatic composition containing FVIIa together with a biologically compatible carrier which permits said FVIIa to remain in contact with said bleeding wound.

КОМПОЗИЦИИ МАТРИКСНЫХ ПРОТЕИНОВ ДЛЯ ЗАЛЕЧИВАНИЯ РАН

Предложено: новая композиция матриксных протеинов для лечения язв, пролежней, свищей, укусов, ран донорных участков и для лечения или профилактики бактериальных инфекционных заболеваний кожи или слизистой оболочки, а также соответствующий способ лечения. Активным веществом композиций предложены белки-предшественники зубной эмали, представляющие собой амелогенины, неамелогенины, обогащенные пролином неамелогенины, амелины и тафтелины, их производные и смеси (перечень последовательностей аминокислот представлен). Изобретение расширяет арсенал средств указанного назначения. 3 с. и 27 з.п.ф-лы, 10 ил., 10 табл.

MATRIX PROTEIN CONTAINING COMPOSITIONS FOR INFLAMMATORY ONES AND INFECTIOUS ONES OF CONDITIONS

DEVICE COATED CHARACTERISTICS HOMOGENEOUS WITH OSTEOINDUKTIVEN AND OSTEOKONDUKTIVEN

BONE SCREEN END MATERIAL

FIBROINZUSAMMENSETZUNGEN AND PROCEEDING TO THEIR PRODUCTION

FIXED PHASE SPACE AVERAGE TO THE VASCULAR OKKLUSION WITH MORE IMMOBILIZE THROMBOZYTEN BINDUNGSSUBSTANZ

COMPOSITIONS FOR THE FABRIC ADHESION

Hemostatic compositions containing sterile thrombin

Hydrogel incorporated with bone growth promoting agents for dental and oral surgery

Functionalized surgical adhesives

A bioadherent composition includes a first mixture containing a plurality of reactive members of a specific binding pair, said reactive members being bound to a ligand capable of binding a receptor on biological tissue, and a second mixture containing a plurality of complementary reactive members of the specific binding pair, said complementary reactive members being bound to a ligand capable of binding a receptor on biological tissue, said reactive members capable of forming covalent bonds with said complementary reactive members via a reaction selected from Huisgen cycloaddition reactions, Diels-Alder reactions, and/or thiol-alkene reactions. A method for bonding biological tissue involves utilizing the bioadherent composition.

Composition for tissue welding and method of use

Hemostatic compositions and methods of making thereof

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.

Bioprosthetic tissue repair and reinforcement

A method of reinforcing or repairing a bioprosthetic tissue for use as a prosthetic valve leaflet. The method includes evaluating a bioprosthetic tissue, identifying a defect in the bioprosthetic tissue, and selectively applying an adhesive to a surface of the bioprosthetic tissue at the defect prior to implantation in a patient. A valve assembly comprising a frame and valve leaflets formed of bioprosthetic tissue reinforced selectively applying an adhesive to its surface at a defect. A method of manufacturing a prosthetic heart valve assembling bioprosthetic tissue leaflets to a frame by suturing and reinforcing the suturing lines by applying an additive compound at the suturing holes.

SEALANT OR TISSUE GENERATING PRODUCT COMPRISING A PLASMA MATRIX AND GROWTH FACTORS

The present invention is related to a sealant or a tissue generating product comprising a (coagulated) plasma matrix, one or more growth factors, at least one phospholipid and a protein scatffold for the generation of said tissue (or the coagulation factor VII).

FLOWABLE HEMOSTATIC GEL COMPOSITION AND ITS METHODS OF USE

A method of inhibiting bleeding from an open surgical site includes mixing (i) a flowable gel solution comprising a biopolymer dissolved in a first solvent and (ii) a flowable hardener solution comprising a cross-linking agent dissolved in a second solvent to form a flowable hemostatic gel composition. The method also includes applying the flowable hemostatic gel composition to the open surgical site. The cross-linking agent links chains of the biopolymer together to form a solid hydrogel that inhibits bleeding from the surgical site.

TISSUE-ADHESIVE FORMULATIONS

A tissue-adhesive formulation consists of a naturally occurring or synthetic polymerisable and/or cross-linkable material in particulate form, the polymerisable and/or cross-linkable material being in admixture with particulate material comprising tissue-reactive functional groups. The formulation may be used in the preparation of a tissue-adhesive sheet, by applying the formulation to at least one side of a core of a naturally occurring or synthetic polymeric material.

ONE COMPONENT FIBRIN GLUE COMPRISING A POLYMERIZATION INHIBITOR

Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations.

PROCOAGULANT PEPTIDES AND THEIR DERIVATIVES AND USES THEREFOR

The present invention is directed to a hemostatic or tissue sealing material having (a) a peptide having a sequence SEQ ID NO: 1 or an amino acid analog sequence thereof, and (b) a scaffold for said peptide or amino acid analogue sequence. The scaffold is preferably hemostatic, such as a natural or genetically engineered absorbable polymer, a synthetic absorbable polymer, or combinations thereof. The natural or genetically engineered absorbable polymers can be selected from the group consisting of a protein, a polysaccharide, or combinations thereof.

Antibacterial hemostatic sponge

PLANTABLE PREPARATIONS CONTAINING OF THE GLOBINE, PROCEEDED FOR THEIR MANUFACTURE AND USES

BIO-MEMBRANE FOR TISSUE REGENERATION

A bio-membrane with angiogenic activity for implant in 'tissue regeneration and repair, including bone reconstruction and the repair of skin and soft tissue lesions is described, essentially constituted by a gel able to provide support and growth and/or differentiation and/or angiogenic factors for the full in vivo functionality of the cell, containing also mesenchymal stem/precursor cells, an implant device for reconstructive surgery of bone tissue, of skin and soft tissue lesions which comprises the bio-membrane, and a method for its obtainment. Use of the gel alone for tissue regeneration and of adhesive plasters that comprise it is also described.

IMPLANTABLE PREPARATIONS CONTAINING GLOBIN, METHOD FOR THE PRODUCTION THEREOF AND USES

Preparations containing, in particular, globin which is insoluble at neutral and therefore physiological pH, in which the globin has been obtained from whole blood by depigmention in a medium which extracts or dissolves the haem, but which leaves the globin, and the other constituents that are protein in nature, in a substantially undissolved state, method for producing these preparations, and uses, in particular for tissue filling, healing or regeneration, in particular for chronic wounds and bone healing or regeneration.

FLOWABLE OSTEOGENIC AND CHONDROGENIC COMPOSITIONS

The repair of a cartilage or bone defect is described using a flowable compositions including a chondrogenic agent or osteogenic agent and a biocompatible carrier that is more fluid at ambient temperatures than at elevated temperatures.

Method of Use of Bioactive Materials

A bioactive material is made using fibroin solutions and suspensions designed to support the constructions, repair, regeneration or augmentation of bone and other tissues of the body. The fibroin solutions, suspensions, and composites can be injected to fill cavities or to replace missing tissue. After injection, the materials can produce a scaffold capable of promoting tissue regeneration while degrading. The ability to inject the fibroin solutions, suspensions and composites can reduce the need for many types of surgical procedures that are used to replace or repair bone and other tissues. The fibroin solutions and suspensions are particularly useful for methods of tissue construction and/or repair.

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.

ONE COMPONENT FIBRIN GLUE COMPRISING A POLYMERIZATION INHIBITOR

Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations. 113-. (canceled)14. A method for preparing a sealant at a surface comprising: providing a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 , 21 , 22 , 23 , 24 , and 25° C.; and applying the formulation to the surface under conditions which facilitate fibrin polymerization at the surface.15. The method of claim 14 , wherein the conditions comprise removing claim 14 , blocking claim 14 , neutralizing and/or diluting the GPRP peptide.1620-. (canceled)21. A method of healing claim 14 , sealing and/or reducing blood loss in a subject in need claim 14 , comprising applying to the subject an effective amount of a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 claim 14 , 21 claim 14 , 22 claim 14 , 23 claim 14 , 24 claim 14 , and 25° C.22. (canceled) The instant application contains a Sequence Listing, which is submitted concomitantly with this application via EFS-Web in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 22, 2013, is named “sequencelisting” and is 8 ...

HYDROGELS AND USE THEREOF IN ANASTOMOSIS PROCEDURES

This disclosure provides novel hydrogels that can undergo multiple gel-sol transitions and methods of making and using such hydrogels, particularly in anastomosis procedures. The peptide hydrogels comprising a fibrillar network of peptides that are in an amphiphilic β-hairpin conformation. The peptides comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel. Isolated peptides for making the disclosed hydrogels are provided, as are methods of using the peptide hydrogels in anastomosis procedures. 1. A peptide hydrogel comprising a fibrillar network of peptides , wherein:the hydrogel undergoes a gel-sol phase transition upon application of shear stress, and a sol-gel phase transition upon removal of the shear stress; andthe peptides are in an amphiphilic β-hairpin conformation and comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel.2. The peptide hydrogel of claim 1 , wherein:the amphiphilic β-hairpin conformation comprises a β-turn, a first β-strand, a second β-strand, a hydrophobic face, and a hydrophilic face;the assembly of the peptides in the fibrillar network comprises hydrophobic interactions between the hydrophobic faces of the peptides;the first β-strand comprises the photocaged glutamate residue, the second β-strand comprises a glycine residue, and the sidechains of the photocaged glutamate residue and the glycine residue are proximal to each other on the hydrophobic faces of the peptides; anduncaging the photocaged glutamate residues disrupts the hydrophobic interactions between the peptides by exposing negative charges of the glutamate residues, thereby disrupting the fibrillar network and triggering the irreversible gel-sol phase transition ...

LIQUID EMBOLIC AGENT COMPOSITION

Provided is a liquid embolic agent composition capable of solving problems of conventional embolic agents, which can be used in a treatment of a vascular disease such as cerebral aneurysm. The problems are solved by a liquid embolic agent composition characterized in containing a hydrogel forming component having a calcium ion entrapping ability, and an anti-biodegradation component. The hydrogel forming component having a calcium ion entrapping ability is at least one kind of acidic polysaccharide selected from the group consisting of alginate, gellan gum, carrageenan, and carboxymethyl cellulose salt; and the anti-biodegradation component is at least one kind selected from the group consisting of hydroxypropyl methylcellulose, methylcellulose, polyvinyl alcohol, polyallylamine, poly-N-vinyl acetamide, and cellulose acetate. 19-. (canceled)10. A liquid embolic agent composition which comprises:a hydrogel forming component having a calcium ion entrapping ability; andan anti-biodegradable component,wherein the hydrogel forming component having a calcium ion entrapping ability comprises sodium alginate and gellan gum,wherein the anti-biodegradable component is hydroxypropyl cellulose, andwherein the liquid embolic agent composition is in a liquid state in vitro, and gelates by reacting with calcium ions in blood to exhibit a bioadhesiveness in vivo.11. The liquid embolic agent composition according to claim 10 , further comprising a coagulation promoting component claim 10 , wherein the coagulation promoting component is at least one selected from the group consisting of colloidal silica claim 10 , poly(N claim 10 ,N-dimethyl) acrylamide claim 10 , an enzyme preparation for food processing claim 10 , poly-L-lysine hydrobromide claim 10 , poly-L-glutamic acid sodium salt claim 10 , chitosan claim 10 , and silk fibroin.12. The liquid embolic agent composition according to claim 10 , which is used for treating cerebral aneurysm.13. The liquid embolic agent composition ...

SELF-ASSEMBLING PEPTIDE COMPOSITIONS

The present disclosure provides peptide compositions (e.g., of self-assembling peptides) with particular attributes (e.g., peptide identity, peptide concentration, pH, ionic strength [including salt identity and/or concentration), etc that show particularly useful material properties. The present disclosure also provides technologies for selecting and/or formulating particular peptide compositions useful in specific contexts. In some embodiments, provided peptide compositions have an elevated pH within the range of about 2.5 to about 3.5 and/or an ionic strength that is above that of a corresponding composition of the same peptide, at the same concentration, in water, but is below a critical salt point for the peptide (e.g., so that the composition is not cloudy). 1. An IEIK13 composition comprising:an IEIK13 peptide at a concentration of at least 0.25%;which composition has a pH within the range of about 2.5 to about 4.0.2. The composition of claim 1 , which composition is a solution.3. The composition of claim 1 , which composition is a gel.4. The composition of claim 1 , wherein the composition has ionic strength within the range of about 0.0001 M to about 0.1 M.5. The composition of claim 4 , wherein the ionic strength is adjusted/given by common salts claim 4 , wherein the common salts are selected from the group consisting of NaCl claim 4 , KCl claim 4 , MgCl claim 4 , CaCl claim 4 , and CaSO.6. The composition of claim 4 , wherein the ionic strength is given by common salts claim 4 , wherein the common salts are composed of one or more salt forming cations and one or more salt forming anions claim 4 , wherein the salt forming cations are selected from the group consisting of ammonium claim 4 , calcium claim 4 , iron claim 4 , magnesium claim 4 , potassium claim 4 , pyridinium claim 4 , quaternary ammonium claim 4 , and sodium claim 4 , wherein the salt forming anions are selected from the group consisting of acetate claim 4 , carbonate claim 4 , chloride ...

SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS

Compositions, methods and delivery devices (e.g., pre-filled syringes) for controlling bleeding during surgical procedures are provided, wherein the compositions are characterized as having an aqueous formulation that is capable of adopting a gelled state upon contact with bodily fluids and/or blood of a patient (i.e., physiological conditions).

Photoactivated crosslinking of a protein or peptide

A method of crosslinking a protein or peptide for use as a biomaterial, the method comprising the step of irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a cross-linking reaction to form a 3-dimensional matrix of the biomaterial.

NOVEL POLYPEPTIDES AND MEDICAL USES THEREOF

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition. 1. A polypeptide comprising or consisting of an amino acid sequence derived from collagen type VI , or a fragment , variant , fusion or derivative thereof , or a fusion of said fragment , variant of derivative thereof ,wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms.2. A polypeptide according to wherein the microorganisms are selected from the group consisting of bacteria claim 1 , mycoplasmas claim 1 , yeasts claim 1 , fungi and viruses.3. A polypeptide according to any one of the preceding claims wherein the polypeptide is capable of binding to the membrane of the microorganism.4. A polypeptide according to any one of the preceding claims wherein the polypeptide is capable of causing membrane disruption of the microorganisms.5. A polypeptide according to any one of the preceding claims which is capable of promoting wound closure.6. A polypeptide according to any one of the preceding claims claim 1 , wherein the polypeptide is capable of exhibiting an antimicrobial effect greater than or equal to that of LL-37.7. A polypeptide according to any one of ...

CEREBROSPINAL FLUID LEAKAGE OCCLUSION

Methods and materials for treating a cerebrospinal fluid leakage are described herein. One method for treating cerebrospinal fluid leakage includes occluding cerebrospinal fluid leakage by administering an effective amount of a self-assembling peptide solution to a target area of a cerebrospinal fluid leakage, where the self-assembling peptide is between 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions. 1. (canceled)2. A method for treating cerebrospinal fluid leakage , the method comprising administering an effective amount of a self-assembling peptide solution to an area of dura associated with the cerebrospinal fluid leakage , wherein the self-assembling peptide is between 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions;{'sup': 2', '2, 'wherein the effective amount is approximately 0.1 mL per 1 cmto approximately 5 mL per 1 cmof a site of the cerebrospinal fluid leakage; and'}the self-assembling peptide is about 0.1 to about 3.5 w/v % of the self-assembling peptide solution.3. The methods of claim 1 , wherein the target area comprises an area of dura associated with cerebrospinal fluid leakage.4. The method of claim 1 , wherein the hydrogel mitigates cerebrospinal fluid leakage.5. The method of claim 1 , wherein the hydrogel substantially prevents cerebrospinal fluid leakage.6. The method of claim 2 , wherein the self-assembling peptide comprises about 12 to about 16 amino acids that alternate between hydrophobic and-a hydrophilic amino acids.7. The method of claim 2 , wherein the self-assembling peptide comprises a sequence selected from RADA (SEQ ID NO:1) claim 2 , IEIK (SEQ ID NO:2) claim 2 , TTTT (SEQ ID NO:3) claim 2 , ATAT (SEQ ID NO:4) claim 2 , TVTV (SEQ ID NO:5) claim 2 , ASAS (SEQ ID NO:6) claim 2 , SSSS (SEQ ID NO:7) claim 2 , VVVTTTT (SEQ ID NO:8) claim 2 , and a combination thereof.8. ...

TREATMENT FOR BILE LEAKAGE

Materials and methods for treating bile leakage are disclosed. A peptide comprising between about 7 amino acids to about 32 amino acids may be introduced to a target site. The peptide may undergo self-assembly upon adjustment of a pH level of the solution to a physiological pH level. 1. A method of treating a bile leakage in a subject comprising:positioning an end of a delivery device in a target area of the bile leakage in which an occlusion is desired;administering through the delivery device a solution comprising a self-assembling peptide comprising between about 7 amino acids and about 32 amino acids in an effective amount and in an effective concentration to form a hydrogel under conditions surrounding the bile leakage to provide an occlusion of the bile leakage;removing the delivery device from the target area of the bile leakage.2. The method of claim 1 , further comprising visualizing a region comprising at least a portion of the target area surrounding the bile leakage.3. The method of claim 2 , wherein visualizing the region comprises visualizing the region during at least one of:identifying the target area of the bile leakage;positioning the end of the delivery device in the target area;administering the solution;removing the delivery device; andmonitoring the bile leakage after removing the delivery device.4. The method of claim 3 , wherein visualizing the region provides for selective administration of the solution to the target area of the bile leakage.5. The method of claim 3 , further comprising visualizing the region in a time period of about one minute subsequent to administering the solution.6. The method of claim 5 , further comprising visualizing the region in a time period of about three minutes subsequent to administering the solution.7. The method of claim 6 , further comprising visualizing the region in a time period of about one week subsequent to administering the solution.8. The method of claim 1 , wherein at least one of the effective ...

Injectable Biodegradable Bone Matrix for Multiple Myeloma Lesion Augmentation and Osteoporosis

Bone filler compositions, methods of making and using the same, and methods of treating osteoporosis and cancer-induced bone defects, are described.

FLOWABLE HEMOSTATIC GEL COMPOSITION AND ITS METHODS OF USE

A flowable hemostatic gel composition is provided for use at a site of a defect within a biological tissue. The flowable hemostatic gel composition includes a flowable gel solution that includes a biopolymer dissolved in a first solvent. The biopolymer is configured to cross-link with red blood cells at the site to facilitate clot formation at the site. The flowable hemostatic gel composition also includes at least one additional active agent. 1. A method of inhibiting bleeding from a site of a defect within a biological tissue , said method comprising applying a flowable hemostatic gel composition to the site such that a biopolymer of the flowable hemostatic gel composition cross-links with red blood cells at the site to facilitate clot formation at the site , the flowable hemostatic gel composition including:a flowable gel solution that includes the biopolymer dissolved in a first solvent, andat least one additional active agent.2. The method of claim 1 , wherein said applying the flowable hemostatic gel composition comprises flowing the flowable hemostatic gel composition out of a lumen of an injection device.3. The method of claim 1 , wherein said applying the flowable hemostatic gel composition comprises applying the biopolymer that is substantially polycationic dissolved in the first solvent that is a dilute acid.4. The method of claim 3 , wherein said applying the flowable hemostatic gel composition comprises applying the biopolymer that includes chitosan dissolved in the first solvent that includes lactic acid.5. The method of claim 1 , wherein said applying the flowable hemostatic gel composition comprises applying the at least one additional active agent that includes at least one clotting agent.6. The method of claim 5 , wherein said applying the flowable hemostatic gel composition comprises applying the at least one clotting agent that is at least one of thrombin and fibrinogen.7. The method of claim 6 , wherein said applying the flowable hemostatic gel ...

FLOWABLE HEMOSTATIC GEL COMPOSITION AND ITS METHODS OF USE

A method of inhibiting bleeding from an open surgical site includes mixing (i) a flowable gel solution comprising a biopolymer dissolved in a first solvent and (ii) a flowable hardener solution comprising a cross-linking agent dissolved in a second solvent to form a flowable hemostatic gel composition. The method also includes applying the flowable hemostatic gel composition to the open surgical site. The cross-linking agent links chains of the biopolymer together to form a solid hydrogel that inhibits bleeding from the surgical site. 1. A method of inhibiting bleeding from an open surgical site , said method comprising:mixing (i) a flowable gel solution comprising a biopolymer dissolved in a first solvent and (ii) a flowable hardener solution comprising a cross-linking agent dissolved in a second solvent to form a flowable hemostatic gel composition; andapplying the flowable hemostatic gel composition to the open surgical site, wherein the cross-linking agent links chains of the biopolymer together to form a solid hydrogel that inhibits bleeding from the surgical site.2. The method of claim 1 , wherein said mixing the flowable gel solution and the flowable hardener solution comprises mixing the flowable gel solution and the flowable hardener solution within a lumen of an injection device claim 1 , and said applying the flowable hemostatic gel composition comprises flowing the flowable hemostatic gel composition out of the lumen of the injection device.3. The method of claim 1 , wherein said mixing the flowable gel solution and the flowable hardener solution comprises mixing the flowable gel solution and the flowable hardener solution prior to introducing the flowable hemostatic gel composition into a lumen of an injection device claim 1 , and said applying the flowable hemostatic gel composition comprises flowing the flowable hemostatic gel composition out of the lumen of the injection device.4. The method of claim 1 , wherein said mixing the flowable gel solution ...

Liquid medical material

To provide a liquid medical material maintaining a colloid in a more sol form than a solid at normal temperature, having a higher function as a wound dressing material and a hemostatic material than fibrin glue, and being able to be produced safely and inexpensively. A gelatin aqueous solution including calcium at a concentration of 0.2 M or more and 1.0 M or less, and having a concentration of 5% by weight or more and 40% by weight or less, an average molecular weight of 80,000 or more and 120,000 or less, and a molecular weight distribution of 20,000 or more and 300,000 or less, and transglutaminase inducing crosslinking of the gelatin, are included. It is preferable that the calcium has a concentration of 0.2 M or more and 0.7 M or less, the gelatin has a bloom of 160 or more and 250 or less, and the transglutaminase has activity per unit of 36 U/ml to 400 U/ml.

APPARATUS AND METHOD OF USING IN SITU SOLIDIFYING COMPLEX COACERVATES FOR VASCULAR OCCLUSION

Described herein are the use of fluid complex coacervates that produce solid adhesives in situ to anchor medical devices such as catheters in a blood vessel. The anchored devices permit the targeted delivery of bioactive agents. The anchored devices can perform as an embolic agent by reducing or preventing blood flow in the vessel. Additionally, the embolic produced from the solid adhesive produced in situ can also include one or more bioactive agents that can be released in a controlled manner. 1. A method for anchoring a catheter in a blood vessel of a subject , the method comprising(a) inserting into a blood vessel of a subject a first catheter and a second catheter, wherein the second catheter is extended further into the vessel than the first catheter; and(b) injecting into the first catheter an in situ solidifying complex coacervate to produce an adhesive in the vessel that adheres the second catheter to the inner wall of the vessel, wherein the in situ solidifying complex coacervate comprises at least one polycation, at least one polyanion, and a salt that produces ions in water, wherein the concentration of the ions in the complex coacervate is greater than the concentration of the ions in the blood vessel.2. The method of claim 1 , wherein the first catheter and second catheter are a co-axial catheter.3. The method of claim 1 , wherein the second catheter comprises an occlusion balloon catheter.4. The method of claim 1 , wherein the first catheter and second catheter are sistered to one another.5. The method of claim 4 , wherein the diameter of the first catheter is greater than the diameter of the second catheter.6. The method of claim 5 , wherein the tip of the second catheter extends past the tip of the first catheter.7. The method of claim 1 , wherein the adhesive completely seals the vessel.8. The method of claim 1 , wherein the first catheter is removed from the vessel.9. The method of claim 1 , wherein the second catheter is removed and the resulting ...

Partially-denatured protein hydrogels

Provided herein are partially-denatured protein (e.g., albumin) hydrogels and methods of manufacture (e.g., pH induction) and use (e.g., drug delivery) thereof.

METHOD AND APPARATUS TO CONTROL THE HETEROGENEOUS FLOW OF BONE CEMENT AND IMPROVE OSSEOINTEGRATION OF CEMENTED IMPLANT

The present invention provides processes for combined applications of making grooves on an implant surface, applying MgO nanoparticles with PMMA cement, restricting the cement movement by PCL nanofiber and tethering biomolecules with PCL nanofiber to enhance mechanical stability and osseointegration of PMMA cement with bone. This is achieved through enhanced osteoconductive properties, roughness, and less viable fracture originating sites at the bone-cement interface. Such combined applications of nanoparticle and nanofiber on the mechanical stability and osseointegration of cemented implant is heretofore unknown, but as provided by the present invention can solve the debonding problem of cemented implant from bone. 1. A process providing a method to enhance mechanical stability and osseointegration of PolyMethylMethAcrylate (PMMA) cement with bone in surgeries using a metallic implant , comprising:amending surface areas of said implant using at least one of grooves or ion deposition;mixing nanoparticles as additives with PMMA cement;immobilizing osteoconductive nanomaterials with electrospun nanofibers (ENF), andconstruction of a membrane using said ENF said membrane exhibiting adequate stiffness to control the movement of said cement into said bone,wherein said nanofiber membrane is inserted into a formed cavity in said bone, said PMMA cement is deposited into said nanofiber membrane, and said implant is inserted into said formed cavity.2. The process of claim 1 , wherein microgroves on said implant are coupled with growth factors immobilized collagen-poly-ε-caprolactone nanofiber matrix (CG-PCL NFM).3. The process of claim 1 , wherein fibronectin (FN) and magnesium oxide nanoparticles (MgO NPs) immobilized CG-PCL NFM coating are coupled on said implant.4. The process of claim 1 , further comprising immobilizing cell adhesion matrix protein (collagen claim 1 , fibronectin) and bone growth molecules (rhBMP claim 1 , TGF-β) using said ENF membrane to increase ...

HEMOSTATIC COMPOSITIONS AND METHODS OF MAKING THEREOF

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition. 1. A method of forming a powdered hemostatic composition , comprising the steps of:a) forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent;b) spraying the suspension through a nozzle onto a substrate,c) allowing the non-aqueous solvent to evaporate;d) separating the composition from the substrate and sieving the composition; andthus forming the powdered hemostatic composition.2. The method of claim 1 , wherein said non-aqueous low boiling solvent comprises Hydrofluoroether CFOCH.3. The method of claim 1 , wherein said non-aqueous low boiling solvent comprises HFE7100.4. The method of claim 1 , wherein said suspension further comprises Tris.5. The method of claim 1 , wherein said suspension further comprises calcium chloride.6. The method of claim 1 , wherein said suspension comprises a fibrin sealant powder which comprises about 90% of fibrinogen claim 1 , about 8% of thrombin claim 1 , and about 2.5% calcium chloride by weight.7. The method of claim 6 , wherein said powdered hemostatic composition has a ratio of fibrin sealant powder to ORC from about 1:1 to about 10:1 by weight.8. The method of claim 1 , wherein said powdered hemostatic composition comprises powder having particle size predominantly in the range from about 250 to about 850 microns.9. The method of claim 8 , wherein said powdered hemostatic composition comprises powder having particle size predominantly in ...

Hemostatic Composition And Preparation Method Therefor

Provided is a hemostatic composition comprising trypsin and zeolite, wherein pore channels of the zeolite are micropores, the zeolite contains divalent metal cations, and the mass ratio of the trypsin to the zeolite is 1:200-4:10. In the present invention, the trypsin specifically binds to the zeolite, allowing the trypsin to maintain a certain conformation on the surface of the zeolite and to obtain a higher procoagulant activity, thereby obtaining a hemostatic composition with an excellent blood coagulation effect. The hemostatic composition of the present invention has the advantages of a simple preparation method, low cost and convenient use, and can be widely used in hemostasis during trauma and operations, especially in emergent hemostasis in hemophilia patients.

Implant and insertion device for an implant

Embodiments include an implant for insertion into a human and/or animal body and an insertion device for the implant. The implant includes a housing, at least one negative pressure unit and at least one adhesive application unit to temporarily and/or permanently fix the implant to a bodily tissue.

Systemic and Topical Application of Platelet Microparticles to Treat Bleeding in Trauma Patients

The present disclosure is directed to blood dotting compositions comprising platelet microparticles, method of using said compositions, and methods of preparing the same. 1. A blood clotting composition comprising:isolated platelet microparticles; one or more factors selected from fibrinogen (Factor I), von Willebrand factor, Factor II, Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Factor XII, Protein C (PC), Protein S (PS), antithrombin III (ATIII); and a pharmaceutical carrier;wherein fibrinogen is at about 10-1000 mg/deciliter (dL), Factor V is at about 0.5-2.0 International Unit (IU), Factor VII is at about 0.5-4.0 IU, Factor VIII is at about 0.2-2.0 IU, Factor IX is at about 0.5-3.0 IU, Factor XI is about 0.5-3.0 IU, Factor XII is at about 1.0-7.0 IU, Protein C (PC) is at about 25-300% activity, Protein S (PS) is at about 10-150% activity, antithrombin III (ATIII) is about 25-250% activity.2. The composition of claim 1 , wherein the composition has either prothrombin time that is within a normal reference range or an activated partial thromboplastin time that is within a normal reference range.3. (canceled)4. The composition of claim 1 , wherein the composition has a blood clot initiation time (R-time) of less than three minutes when measured using thromboelastography.5. The composition of claim 1 , wherein the concentration of platelet microparticles in the composition is >10″ microparticles/μl.6. The composition of claim 1 , wherein the composition comprises two or more of the factors or all eight factors.7. (canceled)8. The composition of claim 1 , wherein the composition is formulated for topical administration or systemic administration.9. The composition of claim 8 , wherein the composition is formulated as a spray claim 8 , powder claim 8 , cream claim 8 , gel claim 8 , or ointment.10. (canceled)11. A wound dressing comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the blood clotting composition of and'}a wound dressing ...

Haemostatic wound dressing

Haemostatic wound dressings are described. The dressings comprise a non-colloidal porous dressing material, and a plurality of fibrinogen-binding peptides immobilised to the non-colloidal porous dressing material, wherein each fibrinogen-binding peptide comprises: an amino acid sequence Gly-Pro-Arg-Xaa (SEQ ID NO: 1) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Val, preferably Pro, Sar, or Leu; or an amino acid sequence Gly-His-Arg-Xaa (SEQ ID NO: 2) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Pro. The dressings are able to accelerate haemostasis without requiring enzymatic activity. In particular, the dressings to do not rely on the action of exogenous thrombin, and can be stored long-term at room temperature in solution. Methods of making the dressings, and use of the dressings to control bleeding are also described.

BIOMATERIALS AND METHODS RELATED THERETO

The present invention relates to biocompatible compositions comprising one or more crystallin proteins, and the use of such compositions in therapeutic and research methods, for example in surgical methods, in sustained release drug delivery, and in cell-based methods. 1. A biocompatible composition comprising:{'claim-text': ['a. an α-crystallin;', 'b. a β-crystallin;', 'c. a γ-crystallin;', {'i': 'Macruronus novaezelandiae', '#text': 'd. a protein from any one of a) to c) above from Hoki ();'}, {'i': 'Homo sapiens;', '#text': 'e. a protein from any one of a) to c) above from'}, 'f. a protein comprising the amino acid sequence identified in Table 1 herein;', 'g. a polypeptide comprising or consisting of at least about 10 contiguous amino acids from any one of a) to f) above;', 'h. a protein having at least about 90% amino acid identity to any one of a) to g) above;', 'i. a protein according to any one of a) to h) above having the native structure of a crystallin protein in vivo;', 'j. any combination of two or more of a) to i) above;'], '#text': 'one or more isolated, purified, recombinant, or synthesised proteins selected from the group comprising:'}optionally one or more plasticizers;optionally one or more co-initiators; andone or more crosslinkers.2. The biocompatible composition according to claim 1 , wherein said one or more proteins are crosslinkable to form a polymer.3. The biocompatible composition according to or claim 1 , wherein the biocompatible composition is an in vivo gelling composition formulated to at least in part polymerise and/or gel at a target site in or on a subject's body claim 1 , or wherein the biocompatible composition is an in vivo gelling composition formulated such that crosslinking of the in vivo gelling composition occurs or is initiated when present at a target site in or on a subject's body.4. A method for producing a crosslinked biopolymer composition claim 1 , the method comprising:{'claim-text': ['a. an α-crystallin;', 'b. a β- ...

Blood Coagulation-Promoting Silk Fibroin-Polypeptide Electrospun Membrane and Preparation Method Thereof

The present invention discloses a blood coagulation-promoting silk fibroin-polypeptide electrospun membrane and a preparation method thereof. The electrospun membrane is made by using silkworm silk fibroin as a carrier and adding the polypeptide GPRPPSEHLQIT. It is mainly used for promoting blood coagulation, and is a blood coagulation material that can targetedly bind to human fibrinogen. The preparation method includes the steps of dissolving, filtering, dialyzing, concentrating and freeze-drying silkworm cocoons after degumming to obtain silk fibroin freeze-dried powder. The polypeptide used in the present invention is a polypeptide obtained by self-screening. Compared with other polypeptides, it can specifically targetedly bind to human fibrinogen. 1. A blood coagulation-promoting silk fibroin-polypeptide electrospun membrane , wherein the polypeptide has a sequence of GPRPPSEHLQIT (SED ID NO: 1).2. The silk fibroin-polypeptide electrospun membrane according to claim 1 , wherein the electrospun membrane is made of interwoven silk fibroin nanofibers claim 1 , and the polypeptide is evenly distributed in the nanofibers.3. A preparation method of the blood coagulation-promoting silk fibroin-polypeptide electrospun membrane according to claim 1 , wherein specific preparation steps adopted are as follows:1) dissolving, filtering, dialyzing, concentrating, freeze-drying silkworm cocoons after degumming to obtain silk fibroin freeze-dried powder;2) evenly mixing the silk fibroin freeze-dried powder and the polypeptide GPRPPSEHLQIT (SED ID NO: 1) with a hexafluoroisopropanol solvent;3) electrospinning a mixed solution obtained in step 2) to obtain a silk fibroin-polypeptide electrospun membrane.4. The preparation method of the silk fibroin-polypeptide electrospun membrane according to claim 3 , wherein the mass ratio of the silk fibroin freeze-dried powder:the hexafluoroisopropanol solvent used in the step 2) is 2: 98-20:80.5. The preparation method of the silk fibroin- ...

Device having osteoinductive and osteoconductive properties

The present invention relates to a device having osteoinductive and osteoconductive properties in vivo comprising a carrier containing calcium phosphate and an osteoinductive protein, wherein the carrier is homogenously coated with the protein. Moreover, the present invention relates to a method for the production of a device having osteoinductive and osteoconductive properties in vivo. The invention encompasses a pharmaceutical composition comprising the device of the invention or a device which is obtainable by the method of the invention and relates to the use of the device for the preparation of a pharmaceutical composition to be used for bone augmentation, for treating bone defects, for treating degenerative and traumatic disc disease, for treating bone dehiscence or to be used for sinus floor elevation. Finally, the invention relates to a kit comprising the device of the invention or a device which is obtainable by the method of the invention.

HEMOSTATIC COMPOSITIONS AND METHODS OF MAKING THEREOF

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition. 1. A method of forming a powdered hemostatic composition , comprising the steps of:a) forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent;b) spraying the suspension through a nozzle onto a substrate,c) allowing the non-aqueous solvent to evaporate;d) separating the composition from the substrate and sieving the composition; and thus forming the powdered hemostatic composition.2. The method of claim 1 , wherein said non-aqueous low boiling solvent comprises Hydrofluoroether C4F9OCH3.3. The method of claim 1 , wherein said non-aqueous low boiling solvent comprises HFE7100.4. The method of claim 1 , wherein said suspension further comprises Tris.5. The method of claim 1 , wherein said suspension further comprises calcium chloride.6. The method of claim 1 , wherein said suspension comprises a fibrin sealant powder which comprises about 90% of fibrinogen claim 1 , about 8% of thrombin claim 1 , and about 2.5% calcium chloride by weight.7. The method of claim 6 , wherein said powdered hemostatic composition has a ratio of fibrin sealant powder to ORC from about 1:1 to about 10:1 by weight.8. The method of claim 1 , wherein said powdered hemostatic composition comprises powder having particle size predominantly in the range from about 250 to about 850 microns.9. The method of claim 8 , wherein said powdered hemostatic composition comprises powder having particle size ...

USE OF SELF-ASSEMBLING POLYPEPTIDES AS TISSUE ADHESIVES

The present invention relates to a self-assembling polypeptide for use as tissue adhesive. The present invention also relates to the use of a self-assembling polypeptide as tissue adhesive. Further, the invention is directed to the use of a self-assembling polypeptide to glue one or more cosmetic compounds on skin, mucosa, and/or hair. Furthermore, the invention is directed to a self-assembling polypeptide for use in gluing one or more pharmaceutical compounds on tissue, skin, mucosa, and/or hair. 155.-. (canceled)56. A method for adhering tissue comprising the steps of:(i) providing a self-assembling polypeptide,(ii) applying the self-assembling polypeptide to at least one of at least two tissue layers, thereby coating the at least one of the at least two tissue layers with the self-assembling polypeptide, and(iii) contacting the at least two tissue layers, thereby adhering the at least two tissue layers together.57. The method of claim 56 , wherein said polypeptide further comprises at least one peptide which is capable of enhancing the adhesive effect.58. The method of claim 57 , wherein the adhesive effect is mediated via binding of the peptide to a cell adhesion mediating protein (CAMP).59. The method of claim 58 , wherein the peptide comprises at least one CAMP recognition sequence.60. The method of claim 59 , wherein the CAMP recognition sequence comprises a module containing RGD claim 59 , GER claim 59 , GEK claim 59 , GEN claim 59 , IDAPS (SEQ ID NO: 45) or variants thereof claim 59 , GPR claim 59 , HHLGGAKQAGDV (SEQ ID NO: 46) or variants thereof claim 59 , CDPGYIGSR (SEQ ID NO: 47) or variants thereof claim 59 , AEIDGIEL (SEQ ID NO: 48) or variants thereof claim 59 , QIDS (SEQ ID NO: 49) claim 59 , or LTD.61. The method of claim 56 , wherein the self-assembling polypeptide is a silk polypeptide.62. The method of claim 61 , wherein the silk polypeptide is selected from the group consisting of ADF-3 (SEQ ID NO: 1) or variants thereof claim 61 , ADF-4 (SEQ ...

Kits, formulations and solutions having enzymatically- permissive amounts of visualization agents and uses thereof

The invention relates to a proteolytic enzyme which is capable of forming fibrin when it reacts with fibrinogen, a fibrin-glue kit and a fibrin-glue formulation comprising an enzymatically-permissive concentration of a visualization agent and to their use in methods for prevention and/or reduction of adhesions and/or methods for promotion of blood coagulation sealing or filling body surfaces. 127-. (canceled)28. A method of preparing a fibrin glue at a surface comprising: providing a solution A—comprising fibrinogen; providing a solution B—comprising a proteolytic enzyme which is capable of forming fibrin when it reacts with fibrinogen and an enzymatically-permissive concentration of a visualization agent; applying a defined volume of the solutions to said surface so as to cause clotting of the fibrin.29. The method according to claim 28 , wherein the concentration of the visualization agent in the generated glue is in the range of from about 0.0025 to about 0.1% claim 28 , or from about 0.0025 to about 0.01%.30. The method according to or claim 28 , wherein solutions A and B are applied to said surface simultaneously.31. The method according to any one of to claim 28 , wherein the proteolytic enzyme is thrombin.32. The method according any one of to claim 28 , wherein solution A further comprises a catalyst capable of inducing cross-linking of fibrin.33. The method according to claim 32 , wherein the catalyst is a transglutaminase.34. The method according to claim 33 , wherein the transglutaminase is Factor XIII.35. The method according to any one of to claim 33 , wherein the visualization agent is selected from the group consisting of methylene blue claim 33 , indigo carmine and combinations thereof.36. The method according to claim 35 , wherein the visualization agent is methylene blue.37. The method according to any one of to claim 35 , wherein solution B is protected from light.38. The method according to claim 35 , wherein the visualization agent is indigo ...

VASCULAR EMBOLIC SYSTEM

Systems and methods of blocking a biological vessel are provided. The systems and methods may comprise introducing to the vessel an amphiphilic peptide. The peptide may comprise at least thirteen amino acids that may alternate between a hydrophobic amino acid and a hydrophilic amino acid. The peptide may form a beta- sheet spontaneously in an aqueous solution in the presence of a cation. 1. A method of blocking one or more targeted biological vessels in a subject comprising:introducing a catheter into a target biological vessel;positioning an end of the catheter in, near, upstream or downstream from a target area of a biological vessel in which at least a partial obstruction of the vessel is desired;administering through the catheter a solution comprising an amphiphilic peptide comprising at least 12 amino acids that alternate between a hydrophobic amino acid and a hydrophilic amino acid in an effective amount and in an effective concentration to form a hydrogel at the target site the hydrogel thereby forming at least a partial blockage of the target biological vessel;removing the catheter from the biological vessel with the at least partial obstruction in place.2. The method of claim 1 , wherein the peptide solution comprises a contrast agent.3. The method of claim 2 , further comprising visualizing a region comprising at least a portion of the targeted biological vessel or vessels.4. The method of claim 3 , wherein visualizing the region comprising at least a portion of the biological vessel comprises visualizing the region during at least one of:identifying the target area of the biological vessel;introducing the catheter;positioning the end of the catheter in the target area;administering the solution;removing the catheter; andvisualizing the biological vessel after removing the catheter.5. The method of claim 4 , wherein visualizing the region comprises imaging using X-ray radiography.6. The method of claim 3 , wherein visualizing the region provides for ...

COMPOSITIONS AND METHODS USING STEM CELLS IN CUTANEOUS WOUND HEALING

Provided herein are compositions and methods using stem/progenitor cells in a therapeutic approach for treatment of or promotion of healing of acute and chronic wounds. 1. A fibrin sealant comprising a fibrinogen complex (FC) component , a thrombin component , and a cellular component , wherein concentration of fibrinogen used to form the gel is between from about 2 to about 5 mg/ml , wherein the cellular component comprises one or more of stem/progenitor cells , and wherein the fibrin sealant comprises at least 1.5-2.0×10stem/progenitor cells/cm.2. The composition of claim 1 , stem/progenitor cells are selected from the group consisting of bone marrow derived cells claim 1 , hematopoietic stem cells claim 1 , mesenchymal stem cells claim 1 , peripheral blood stem cells claim 1 , and mixtures and combinations thereof.3. The composition of claim 1 , wherein the stem/progenitor cells are bone marrow derived cells.4. The composition of claim 1 , wherein the stem/progenitor cells are mesenchymal stem cells.5. The composition of claim 1 , wherein the stem/progenitor cells are peripheral blood stem cells.6. A method of using a fibrin sealant claim 1 , comprising: a) combining stem/progenitor cells with a fibrin sealant to form a wound sealant claim 1 , said fibrin sealant comprising calcic thrombin and fibrinogen claim 1 , wherein the concentration of calcic thrombin is about 25 U/ml claim 1 , wherein the concentration of fibrinogen is from about 2 to about 5 mg/ml claim 1 , and wherein the final concentration of stem/progenitor cells is at least from about 1.5 to about 2.0×10stem/progenitor cells/cm; b) administering the fibrin sealant to a cutaneous wound claim 1 , wherein the fibrin sealant is administered in the form of a polymerized gel or spray.7. The method of claim 6 , wherein the fibrin sealant is administered to the site of the wound at least two times over the span of three weeks.8. The method of claim 6 , stem/progenitor cells are bone marrow derived cells ...

PHOTOACTIVATED CROSSLINKING OF A PROTEIN OR PEPTIDE

A method of crosslinking a protein or peptide for use as a biomaterial, the method comprising the step of irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a cross-linking reaction to form a 3-dimensional matrix of the biomaterial. 152-. (canceled)53. A method of crosslinking a protein or peptide for use as a tissue sealant , the method comprising:irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a cross-linking reaction to form a three-dimensional matrix of the tissue sealant.54. The method of claim 53 , wherein the protein or peptide comprises fibrinogen claim 53 , fibrin claim 53 , collagen claim 53 , fibronectin claim 53 , keratin claim 53 , laminin claim 53 , and/or elastin.55. The method of claim 53 , wherein the protein or peptide is isolated from native tissues.56. The method of claim 53 , wherein the protein or peptide is a recombinant protein or peptide.57. The method of claim 53 , wherein the electron acceptor is a persulfate.58. The method of claim 57 , wherein the persulfate is ammonium persulfate or sodium persulfate.59. The method of claim 53 , wherein the photoactivatable metal-ligand complex is an Ru(II) complex.60. The method of claim 59 , wherein the photoactivatable metal-ligand complex is a Ru(II)bipyridyl complex.61. The method of claim 60 , wherein the photoactivatable metal-ligand complex is a tris(bipyridyl)Ru(II) complex62. A method of joining and/or sealing at least one substrate claim 60 , comprising the steps of:applying a tissue sealant comprising: a matrix protein or peptide, a photoactivatable metal-ligand complex, and an electron acceptor to at least one substrate; andirradiating the material to photoactivate the photoactivatable metal-ligand complex, thereby initiating a cross-linking reaction to adhere or join the substrate to an adjacent substrate.63. The ...

PROTEIN BIOMATERIAL AND BIOCOACERVATE VESSEL GRAFT SYSTEMS AND METHODS OF MAKING AND USING THEREOF

The present invention relates to protein biocoacervates and biomaterials vessel graft systems used in cardiovascular applications and other medical applications, the components utilized in the vessel graft systems and the methods of making and using such systems. More specifically the present invention relates to protein biocoacervates and biomaterials vessel graft systems used in various medical applications and/or the devices used in such vessel graft systems including, but not limited to, vessel grafts as drug delivery devices for the controlled release of pharmacologically active agents, tubular grafts, vascular grafts, protein biomaterial sutures and biomeshes, protein biomaterial adhesives and glues, and other biocompatible biocoacervate or biomaterial devices used in the vessel graft systems of the present invention. 1. A fastener comprising one or more components , at least one of the components including a biomaterial formed from one or more precipitated amorphous thermoplastic biocoacervates , the biocoacervate(s) including one or more soluble or solubilized primary proteins combined with one or more glycosaminoglycans and one or more biocompatible solvents.2. The fastener of wherein the one or more primary proteins are selected from the group consisting of collagen claim 1 , laminin claim 1 , bone morphogenic protein and its isoforms that contain glycosaminoglycan binding sites claim 1 , albumin claim 1 , interleukins claim 1 , epidermal growth factors claim 1 , fibronectin claim 1 , thrombin claim 1 , aprotinin and antithrombin III.3. The fastener of wherein the one or more glycosaminoglycans are selected from the group consisting of heparin claim 1 , heparin sulfate claim 1 , keratan sulfate claim 1 , dermatin claim 1 , dermatin sulfate claim 1 , heparin-hyaluronic acid claim 1 , chondroitin claim 1 , chondroitin sulfate claim 1 , chondroitin 6-sulfate claim 1 , chondroitin 4-sulfate claim 1 , chitin claim 1 , chitosan claim 1 , acetyl-glucosamine claim ...

DUAL SYRINGE CARTRIDGE AND HOUSING

A dispensing device and cartridge for simultaneous delivery and mixing of multiple co-reactive materials, the cartridge having proximal and distal ends, and having an elongated holder body with substantially parallel longitudinal voids. Multiple syringe bodies are disposed parallel within the voids and multiple co-reactive materials are separately disposed in the syringe bodies. The dispensing device also includes a longitudinal housing which is structured and arranged to receive the cartridge. 1. A cartridge for storage and delivery of multiple co-reactive materials comprising:an elongated holder body having substantially parallel longitudinal voids with windows into each of the substantially parallel longitudinal voids;multiple hollow cylindrical bodies disposed substantially parallel within said longitudinal voids, said co-reactive materials separately disposed in said multiple hollow cylindrical bodies,wherein the multiple hollow cylindrical bodies have open proximal ends, nozzles at distal ends thereof, and pistons positioned inside, said pistons sealing the open proximal end and slidably moveable within the hollow cylindrical bodies and having no plungers attached.2. The cartridge of claim 1 , further comprising removable closure caps sealing the nozzles.3. The cartridge of claim 1 , further comprising a removable rear closure cap having plugs fitting into the open proximal ends of said multiple claim 1 , substantially parallel hollow cylindrical bodies.4. The cartridge of claim 1 , wherein the open proximal ends have diameters substantially the same as inner diameters of the hollow cylindrical bodies claim 1 , and the nozzles have Luer tapers.5. The cartridge of claim 1 , wherein the hollow cylindrical bodies are glass syringe bodies.6. The cartridge of claim 1 , wherein said co-reactive materials are fibrinogen and thrombin.7. The cartridge of claim 1 , wherein the holder body comprises a longitudinal groove between the substantially parallel longitudinal ...

PROCESS FOR PRODUCING HIGH PURITY FIBRINOGEN AND THROMBIN FOR FIBRIN SEALANT

The present invention relates to a fibrin sealant kit comprising purified fibrinogen and thrombin. The invention particularly relates to an improved chromatographic process for the purification of thrombin and fibrinogen components devoid of any significant plasminogen and other impurities. The absence of plasminogen facilitates the exclusion of a proteolytic inhibitor (aprotinin) from among the kit components. 1. An integrated method for the isolation and purification of plasma derived fibrinogen and thrombin , without the use of ethanol precipitation , comprising subjecting plasma to gel filtration chromatography to obtain three fractions (Fraction I , Fraction II and Fraction III) which are subjected to further all-chromatographic steps followed by viral inactivation.2. A method according to comprises isolation followed by purification of fibrinogen claim 1 , involving:a) collection of a fraction from gel chromatography of human plasma;b) addition of ammonium sulphate to a concentration of 0.05M to 0.5M;c) loading on a hydrophobic column (HIC);d) conducting S/D virus inactivation for elute obtained from step c;e) subjecting the treated solution from step d to anion chromatography for further purification;f) conducting virus inactivation for achieving high levels of fibrinogen purity;g) filtration of the solution obtained from step f; andh) formulation and lyophilisation of the solution obtained from step g.3. A method according to comprises isolation followed by purification of thrombin claim 1 , involvinga) collection of a fraction through gel chromatography of human plasma;b) loading the fraction onto an anion exchange column equilibrated with a buffer comprising an acetate, citrate or similar salt with a molarity of 0.01 M to 0.1 M in the pH range of 6.5 to 8.5, eluting a partially purified prothrombin with the same buffer containing sodium chloride;c) conducting S/D virus inactivation for enveloped virus;d) collecting purified prothrombin by elution with a ...

FIBROUS PROTEINACEOUS NETWORKS AND METHODS OF USE THEREOF

Disclosed herein are engineered bacteria that manufacture biofilms from bacterial amyloid structures. These biofilms and biofilm matrices are capable of generating fibrous proteinaceous networks and being used as 3D-printing inks. 1. An amyloid fusion protein comprising an amyloid protein fused to a fibrous protein.2. The amyloid fusion protein of claim 1 , wherein the amyloid protein is selected from the group consisting of CsgA and fragments thereof claim 1 , A-beta claim 1 , alpha-synuclein claim 1 , TasA claim 1 , and Sup35.3. The amyloid fusion protein of claim 1 , wherein the amyloid protein is CsgA claim 1 , or a fragment thereof.4. The amyloid fusion protein of claim 1 , wherein the fibrous protein is selected from the group consisting of keratin claim 1 , elastin claim 1 , fibrin claim 1 , and collagen claim 1 , or a fragment thereof.5. The amyloid fusion protein of claim 4 , wherein the fibrous protein is fibrin claim 4 , or a fragment thereof.6. The amyloid fusion protein of claim 5 , wherein the fibrous protein comprises an α chain of a fibrinogen.7. (canceled)8. The amyloid fusion protein of claim 5 , wherein the fibrous protein comprises a γ chain of a fibrinogen.9. (canceled)10. The amyloid fusion protein of claim 1 , wherein the fibrous protein is a keratin.11. The amyloid fusion protein of claim 10 , wherein the fibrous protein comprises a K5 keratin.12. (canceled)13. The amyloid fusion protein of claim 10 , wherein the fibrous protein comprises a K14 keratin.14. (canceled)15. A plurality of amyloid fusion proteins comprising a first amyloid fusion protein and a second amyloid fusion protein claim 10 ,wherein the first amyloid fusion protein comprises a first amyloid protein fused to a first fibrous protein; andwherein the second amyloid fusion protein comprises a second amyloid protein fused to a second fibrous protein,wherein the first fibrous protein is aggregated with the second fibrous protein.16. The plurality of amyloid fusion proteins of ...

METHODS AND COMPOSITIONS FOR TISSUE ADHESIVES

Disclosed herein are methods of connecting disrupted tissue, tissue repair, treating colorectal disorder and tissue welding. The methods comprise using a bioadhesive composition comprising ELP and light absorbing chromophores and irradiating the bioadhesive tissue. 134.-. (canceled)35. A bioadhesive composition comprising:a photothermally responsive composition comprising collagen, silk protein, or a combination thereof chemically conjugated to a light absorbing chromophore,wherein the light absorbing chromophore is entrapped within the collagen, silk protein, or combination thereof.36. The bioadhesive composition of claim 35 , wherein the light absorbing chromophore comprises silver nanoparticles claim 35 , gold nanorods claim 35 , or gold nanoparticles claim 35 , or mixtures thereof.37. The bioadhesive composition of claim 35 , wherein the bioadhesive composition further comprises an active agent claim 35 , cells claim 35 , or a combination thereof.38. The bioadhesive composition of claim 37 , wherein the active agent comprises an antibacterial agent.39. The bioadhesive composition of claim 37 , wherein the active agent comprises an MMP inhibitor claim 37 , a soluble factor claim 37 , a cytokine claim 37 , or a growth factor.40. The bioadhesive composition of claim 39 , wherein the soluble factor comprises FGF (fibroblast growth factor) claim 39 , TGF-beta claim 39 , EGF or other factors known as growth factors or cytokines claim 39 , or known to be involved in wound healing and repair.41. A bioadhesive composition comprising:a photothermally responsive composition comprising collagen, silk protein, or a combination thereof chemically conjugated to a light absorbing chromophore,wherein the light absorbing chromophore is entrapped within the collagen, silk protein, or combination thereof,wherein the light absorbing chromophore is configured to convert light to heat upon the application of an effective amount of a directed light beam to the bioadhesive composition, ...

FUNCTIONALIZED SURGICAL ADHESIVES

A bioadherent composition includes a first mixture containing a plurality of reactive members of a specific binding pair, said reactive members being bound to a ligand capable of binding a receptor on biological tissue, and a second mixture containing a plurality of complementary reactive members of the specific binding pair, said complementary reactive members being bound to a ligand capable of binding a receptor on biological tissue, said reactive members capable of forming covalent bonds with said complementary reactive members via a reaction selected from Huisgen cycloaddition reactions, Diels-Alder reactions, and/or thiol-alkene reactions. A method for bonding biological tissue involves utilizing the bioadherent composition. 145-. (canceled)46. A bioadherent composition which comprises:a first mixture containing a plurality of reactive members of a specific binding pair, said reactive members being bound to a first ligand capable of binding a first receptor on biological tissue; anda second mixture containing a plurality of complementary reactive members of the specific binding pair, said complementary reactive members being bound to a second ligand capable of binding a second receptor on biological tissue, said reactive members capable of forming covalent bonds with said complementary reactive members via a reaction selected from the group consisting of Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction.47. The bioadherent composition according to wherein the members of the specific binding pair bind to one another via a Huisgen cycloaddition reaction claim 46 , a Diels-Alder reaction and a thiol-ene reaction.48. The bioadherent composition according to wherein the members of the specific binding pair are alkynes and azides.49. The bioadherent composition according to wherein the reactive member is an alkyne and the complementary reactive member is an azide.50. The bioadherent composition according to wherein the reactive members ...

BIOCOMPATIBLE PHASE INVERTIBLE PROTEINACEOUS COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications. 1. A method of producing a phase invertible composition , said method comprising: (a) a liquid proteinaceous substrate; and', '(b) a liquid crosslinking composition comprising a macromolecular crosslinking agent which comprises a reaction product of an excess of a liquid aldehyde crosslinking agent and a glycosaminoglycan, wherein the liquid crosslinking composition has been formed prior to combining with the liquid proteinaceous substrate to produce said phase invertible composition;, 'combining;'}wherein said phase invertible composition is exposed to radiation.2. The method according to claim 1 , wherein the radiation sterilizes the phase invertible composition.3. The method according to claim 1 , wherein the radiation is gamma radiation.4. The method according to claim 1 , wherein the radiation is electron beam radiation.5. The method according to claim 1 , wherein said glycosaminoglycan is hyaluronan.6. The method according to claim 1 , wherein said proteinaceous substrate comprises a proteinaceous material selected from the group consisting of: albumin claim 1 , elastin claim 1 , fibrin and soluble and insoluble forms of collagen and combinations thereof.7. The method according to claim 6 , wherein said crosslinking agent comprises glutaraldehyde.8. The method according to claim 7 , wherein said glutaraldehyde is heat stabilized. This application is a continuation of U.S. patent application Ser. No. 14/055,712 (Attorney Docket No. 30908-703.302 ...

BIOADHESIVE FOR OCCLUDING VESSELS

Bioadhesives and crosslinked gels therefrom are disclosed. The bioadhesives can be applied to a vessel for occluding the vessel. The present disclosure also describes kits that comprise the various components for preparing and applying the bioadhesives. Bioadhesives of the present disclosure include: (i) a biopolymer having one or more first chemically reactive amine groups; (ii) a biocompatible crosslinker having at least two second chemically reactive groups that can chemically react with the one or more first chemically reactive amine groups of the biopolymer; and (iii) a biocompatible rheological modifier. 1. A bioadhesive comprising: (i) a biopolymer having one or more first chemically reactive amine groups; (ii) a biocompatible crosslinker having at least two second chemically reactive groups that can chemically react with the one or more first chemically reactive amine groups of the biopolymer; and (iii) a biocompatible rheological modifier , wherein the biopolymer and crosslinker form a crosslinked network and the biocompatible rheological modifier does not substantially react with the biopolymer or the biocompatible crosslinker.2. The bioadhesive of claim 1 , wherein the biopolymer is a protein or a polysaccharide having one or more primary amines as the first chemically reactive groups.3. The bioadhesive according to wherein the biopolymer is albumin.4. The bioadhesive according to claim 1 , wherein the biocompatible crosslinker is a multi-arm polyethylene glycol (PEG) having at least two or more N-hydroxysuccinimide (NHS) ester groups as the second chemically reactive groups.5. The bioadhesive according to claim 1 , wherein the biocompatible rheological modifier is hyaluronic acid or a salt thereof.6. The bioadhesive according to claim 1 , wherein the biocompatible rheological modifier is a shear thinning fluid with a non-sheared viscosity between 0.5 Pa·s and 200 Pa·s.7. The bioadhesive according to claim 1 , wherein the biopolymer is an albumin having ...

ONE COMPONENT FIBRIN GLUE COMPRISING A POLYMERIZATION INHIBITOR

Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations. 1. A liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide or other reversible fibrin polymerization blocking agent; wherein the blocking agent or GPRP is present in the formulation in an amount which is greater than 100 fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 , 21 , 22 , 23 , 24 , and 25° C.2. The formulation of claim 1 , wherein the GPRP peptide is present in an amount greater than about 340 fold molar excess relative to the fibrin monomers.3. The formulation of claim 1 , wherein the GPRP peptide is present in an amount of about 340 to 460 fold molar excess relative to the fibrin monomers.4. The formulation of claim 1 , wherein the formulation is substantially free of added thrombin.5. The formulation of claim 1 , further comprising thrombin-activated Factor XIII.6. The formulation of claim 1 , further comprising a calcium chelator.7. The formulation of claim 6 , wherein the calcium chelator is a citrate ion.8. The formulation of claim 7 , wherein the citrate ion is provided by sodium citrate.9. The formulation of claim 8 , comprising from about 1 mM to about 50 mM sodium citrate.10. The formulation of claim 1 , wherein the formulation has a neutral pH.11. The formulation of claim 1 , for use in hemostasis claim 1 , sealing claim 1 , healing and/or in surgery.12. A container comprising the formulation of .13. A kit comprising the container of claim 12 , and optionally instructions for use.14. A method for preparing a sealant at a surface comprising providing the formulation of ; and applying the formulation to the surface under conditions which facilitate fibrin polymerization at ...

SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS

Compositions, methods and delivery devices (e.g., pre-filled syringes) for controlling bleeding during surgical procedures are provided, wherein the compositions are characterized as having an aqueous formulation that is capable of adopting a gelled state upon contact with bodily fluids and/or blood of a patient (i.e., physiological conditions). 171-. (canceled)72. A pre-filled syringe for use in a surgical procedure comprising:a barrel comprising a 0.1-10% peptide solution, wherein the peptide has an amino acid sequence that consists of alternating hydrophilic and hydrophobic amino acids; and wherein the peptide solution is characterized by an ability to transition between two states: an ungelled state adopted when one or more particular ions is substantially absent, and a gelled state adopted when the one or more ions is present at or above a threshold level, wherein the one or more ions is or becomes present in the location; and, a non-metal nozzle; wherein said barrel and non-metal nozzle are capable of forming a secure connection in a liquid-tight manner.7388-. (canceled)89. A liquid composition comprising a peptide , wherein the peptide has an amino acid sequence that consists of alternating hydrophilic and hydrophobic amino acids , for use in a surgical procedure performed at an internal site in a subject's body , which composition is characterized by an ability to transition between two states:an ungelled state adopted when one or more particular ions is substantially absent; anda gelled state adopted when the one or more ions is present at or above a threshold level, wherein the one or more ions is or becomes present in the site when the composition is applied thereto.90. A surgical procedure comprises steps of:(a) making an incision in a body to access a site including a damaged portion of an internal organ or tissue to remove, repair, or replace some or all of the damaged portion during the first period of time;{'claim-ref': {'@idref': 'CLM-00091', 'claim ...

PROTEIN-BASED ADHESIVE AND ITS MODIFICATION

This invention relates to protein-based adhesives that are capable to adhere to a substrate in a dry, wet, moist, or an aqueous environment. Particularly, said adhesives comprise a crosslinking agent and an elastin-like polypeptide (ELP) that contain tyrosine, lysine, cysteine, dihydroxyphenylalanine (DOPA) or trihydroxyphenylalanine (TOPA) amino acid residue, or a combination thereof, on the polypeptide chain of said ELP. Among others, the adhesives disclosed herein may find broad applications in medical treatments and surgical operations. Compositions and methods of use are within the scope of this application. 1. An adhesive comprising a crosslinking agent and an elastin-like polypeptide (ELP) , wherein polypeptide chain of said ELP comprises tyrosine , lysine and cysteine residues , or a derivative thereof.2. The adhesive of further comprising an oxidizing agent.3. The adhesive of claim 2 , wherein said oxidizing agent comprises a ferric salt claim 2 , hydrogen peroxide claim 2 , sodium periodate claim 2 , or an enzyme that transforms the phenolic side chain of tyrosine residues of said ELP.4. The adhesive of claim 1 , wherein said crosslinking agent is an oxidizing agent.5. The adhesive of claim 1 , wherein said ELP comprises SEQ ID NOs: 2 claim 1 , 4 claim 1 , 6 claim 1 , 8 claim 1 , 10 claim 1 , and 14.6. The adhesive of claim 1 , wherein said crosslinking agent comprises trishydroxymethylphosphine (THP) claim 1 , tetrakis(hydroxymethyl)phosphonium chloride (THPC) claim 1 , an N-hydroxysuccinyl ester (NHS) claim 1 , genipin claim 1 , pyridyl disulfide claim 1 , a maleimide claim 1 , a vinylsulfone claim 1 , a haloacetyl claim 1 , or a combination thereof.7. The adhesive of claim 1 , wherein said derivative of tyrosine residue of ELP polypeptide chain is dihydroxyphenylalanine (DOPA) or trihydroxyphenylalanine (TOPA) claim 1 , transformed chemically or enzymatically from said tyrosine residue.8. The adhesive of claim 1 , wherein said tyrosine residue of ELP ...

Lung Volume Reduction Therapy Using Crosslinked Biopolymers

One aspect of the present invention relates to bronchoscopic lung volume reduction using solutions of biopolymers that can be polymerized in situ with a crosslinker and a polymeric additive which accelerates the cross-linking reaction. In certain embodiments, the biopolymer solutions can be in the form of a foam or gel. The biopolymer compositions disclosed herein may also be used for indications other than lung volume reduction, such as sealing fistulas or performing emergency tamponade of vessels.

PEPTIDE HYDROGEL PROPERTIES AND ITS APPLICATIONS

Peptide hydrogels having a self-assembling, 3-dimensional nanofiber matrix are described. The nanofiber matrix comprises an amphiphilic peptide and optionally albumin. The peptide comprises (consists of) a terminal hydrophobic region, a central turning region, and a terminal hydrophilic region. Methods of making such hydrogels are also described, along with methods of using the hydrogels as scaffolding for tissue engineering, hemostatic agents, as well as 3-dimensional cell cultures, and for drug delivery, encapsulation of active agents (therapeutic cells, molecules, drugs, compounds), cell transplantation, cell storage, virus culture and storage. 1. A hemostatic agent useful for promoting blood clotting and/or reducing hemorrhaging , said hemostatic agent comprising a peptide , wherein said peptide is amphiphilic and comprises a terminal hydrophobic region , a central turning region , and a terminal hydrophilic region.2. The hemostatic agent of claim 1 , wherein said peptide is in a solution comprising said peptide dispersed claim 1 , dissolved claim 1 , or suspended in a solvent system.3. The hemostatic agent of claim 1 , wherein said hydrophilic region is derived from a β-spiral motif of spider flagelliform silk protein claim 1 , and said hydrophobic and turning regions are derived from the third trans-membrane segment of subunit IV in the dihydropyridine sensitive human muscle L-type calcium channel.4. The hemostatic agent of claim 1 , further comprising albumin and/or calcium.5. The hemostatic agent of claim 1 , wherein said hydrophobic region consists of 2-15 amino acid residues selected from the group consisting of F claim 1 , L claim 1 , I claim 1 , V claim 1 , A claim 1 , H claim 1 , D claim 1 , P claim 1 , and G claim 1 , wherein at least one amino acid residue is I.6. The hemostatic agent of claim 1 , wherein said hydrophilic region consists of 5-20 amino acid residues claim 1 , wherein at least at least one amino acid residue is G claim 1 , at least one ...

Recombinant polypeptide for promoting scarless wound healing and bioadhesive material including the same

Provided are a recombinant polypeptide in which a small leucine-rich proteoglycan mimetic sequence is attached to a terminal of a mussel adhesive protein, a composition for wound healing including the same, a bioadhesive material, and a preparation method thereof. According to the present disclosure, the recombinant polypeptide in which the small leucine-rich proteoglycan mimetic sequence is attached to the terminal of the mussel adhesive protein has an excellent epidermal regeneration effect in which the wound site is uniformly restored by promoting rapid wound healing at the wound site when being applied to the wound site and inducing formation of collagens which are arranged and concentrated at the wound site, and thus can be usefully used as various drugs, cosmetics, and quasi-drugs.

TISSUE SEALANT COMPOSITIONS, VASCULAR CLOSURE DEVICES, AND USES THEREOF

The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures. 187-. (canceled)88. A method of forming a seal in a biological tissue , the method comprising:administering to a subject an effective amount of a tissue sealant to the biological tissue; andactivating an adhesive material in the tissue sealant, thereby forming the seal in the biological tissue; an adhesive material that is activated to form a seal when contacted with the biological tissue; and', 'an optical dye covalently bonded to, or noncovalently associated with, the adhesive material;, 'wherein the tissue sealant compriseswherein the optical dye exhibits a first optical condition prior to activation of the adhesive material and exhibits a second optical condition distinguishable from the first optical condition after activation of the adhesive material.89. The method according to claim 88 , the method further comprising:exposing the tissue sealant to electromagnetic radiation.90. The method according to claim 88 , the method further comprising:detecting the first optical condition and the second optical condition and ...

Tissue sealant compositions, vascular closure devices, and uses thereof

The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.

BONE PASTES COMPRISING BIOFUNCTIONALIZED CALCIUM PHOSPHATE CEMENTS WITH ENHANCED CELL FUNCTIONS FOR BONE REPAIR

The invention provides injectable, biofunctional agent-containing calcium phosphate cement bone pastes for bone tissue engineering, and methods of making and using the same. 1. A bone paste comprising calcium phosphate cement and one or more biofunctional agents , wherein the biofunctional agents are selected from the group consisting of RGD-containing peptides , fibronectin , fibronectin-like engineered polymer protein (FEPP) , derived extracellular matrix (dECM) , and platelet concentrate.2. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and an RGD-containing peptide claim 1 , wherein RGD-containing peptide is selected from the group consisting of RGD claim 1 , G4RGDSP claim 1 , RGDS claim 1 , GRGD claim 1 , GRGDGY claim 1 , RGDSGGC claim 1 , and GRGDS claim 1 , and wherein RGD-containing peptide is present within a range of about 0.0005% to about 5% by mass.3. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and fibronectin claim 1 , wherein fibronectin is present within a range of about 0.0005% to about 5% by mass.4. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and FEPP claim 1 , wherein FEPP is present within a range of about 0.0005% to about 5% by mass.5. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and dECM claim 1 , wherein dECM is present within a range of about 0.001% to about 10% by mass.6. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and platelet concentrate claim 1 , wherein platelet concentrate is present within a range of about 0.001% to about 10% by mass.7. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and any two of the biofunctional agents.8. The bone paste of claim 1 , wherein the bone paste comprises calcium phosphate cement and any three of the biofunctional agents.9. The bone paste of claim 1 , wherein the ...

MULTIBLOCK COPOLYPEPTIDES OF ELASTIN-BASED POLYPEPTIDES AND MUSSEL FOOT PROTEINS WITH STIMULI-RESPONSIVENESS AND SURFACE-ADHESIVE, METHODS OF PREPARING THEREOF AND USE THEREOF

The present disclosure relates to a multiblock copolypeptide having stimulus responsivity and surface adhesiveness. The multiblock copolypeptide of the present disclosure, which is composed of an elastin-based polypeptide and a mussel foot protein, can form self-assembled core-shell structures and hydrogels exhibiting reversible change in response to temperature stimulation and can be used usefully for biomedical applications due to remarkably superior surface adhesiveness. 1. A multiblock copolypeptide comprising:an elastin-based polypeptide (EBP); anda mussel foot protein (MFP).2. The multiblock copolypeptide according to claim 1 , wherein the multiblock copolypeptide is composed of an arrangement selected from a group consisting of (EBP)(MFP) claim 1 , (EBP)(MFP)(EBP)and (MFP)(EBP)(MFP) claim 1 , wherein the n claim 1 , which is an integer 1 or greater claim 1 , is the number of EBP or MFP repeat unit.3. The multiblock copolypeptide according to claim 1 , wherein the elastin-based polypeptide (EBP) is composed of an amino acid sequence selected from a group consisting of a [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG] block claim 1 , a [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG] block and an [IPAXG IPAXG IPAXG IPAXG IPAXG IPAXG] block claim 1 , wherein the X is an amino acid excluding proline.4. The multiblock copolypeptide according to claim 3 , wherein the X of the [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG] block comprises:A (Ala), G (Gly) and I (Ile) at a ratio of 1:4:1;K (Lys), G (Gly) and I (Ile) at a ratio of 1:4:1;D (Asp), G (Gly) and I (Ile) at a ratio of 1:4:1;E (Glu), G (Gly) and I (Ile) at a ratio of 1:4:1;G (Gly), A (Ala) and F (Phe) at a ratio of 1:3:2;K (Lys), A (Ala) and F (Phe) at a ratio of 1:3:2;D (Asp), A (Ala) and F (Phe) at a ratio of 1:3:2;K (Lys) and F (Phe) at a ratio of 3:3;D (Asp) and F (Phe) at a ratio of 3:3;H (His), A (Ala) and I (Ile) at a ratio of 3:2:1;H (His) and G (Gly) at a ratio of 5:1; orG (Gly), C (Cys) and F (Phe) at a ratio of 1:3:2.5. The ...

SELF-ASSEMBLING UNDERWATER ADHESIVES

Compositions, methods, and kits are provided which involve novel fusion protein-based adhesives for use in medical and marine applications. In some aspects, the novel fusion proteins comprise an adhesive domain (e.g., derived from an adhesive protein of a marine organism) and an amyloid domain (e.g., derived from a bacterial amyloid protein). Also provided are copolymers and fibers of the fusion proteins. 1. A fusion protein comprising an adhesive protein derived from a marine organism , or a fragment thereof , and an amyloid protein , or a fragment thereof.2. The fusion protein of claim 1 , wherein the adhesive protein is a mussel foot protein (Mfp).3Mytilus galloprovincialisMytilus edulis.. The fusion protein of claim 2 , wherein the Mfp is or4. The fusion protein of claim 3 , wherein the Mfp is Mfp3 (SEQ ID NO:1 or SEQ ID NO:3) or Mfp5 (SEQ ID NO:2 or SEQ ID NO:4).5. The fusion protein of claim 1 , wherein the amyloid protein is a bacterial amyloid protein.6Escherichia coli.. The fusion protein of claim 5 , wherein the bacterial amyloid protein is from7. The fusion protein of claim 6 , wherein the bacterial amyloid protein is CsgA (SEQ ID NO:5).8. (canceled)9. The fusion protein of claim 4 , wherein Mfp3 or Mfp5 shares homology that is at least 85% claim 4 , at least 90% claim 4 , at least 95% claim 4 , or at least 98% identical to the wild type amino acid sequence for Mfp3 or Mfp5 claim 4 , respectively.10. The fusion protein of claim 7 , wherein CsgA shares homology that is at least 85% claim 7 , at least 90% claim 7 , at least 95% claim 7 , or at least 98% identical to the wild type amino acid sequence of CsgA.11. The fusion protein of claim 1 , wherein Mfp3 or Mfp5 is fused to the C-terminus of CsgA claim 1 , Mfp3 or Mfp5 is fused to the N-terminus of CsgA claim 1 , or Mfp3 or Mfp5 is fused within CsgA.1215-. (canceled)16. A fusion protein comprising an adhesive protein derived from a marine organism claim 1 , and a thermal-reversible functional domain.17. ...

CELL-SEEDED POROUS LUNG HYDROGEL SEALANT

Disclosed are a biosealant system and method for treatment of a pulmonary air leak comprising applying the biosealant system to the locus of the air leak. 1. A biosealant composition comprising an extracellular matrix hydrogel and a thermogel;wherein the extracellular matrix hydrogel comprises a first extracellular matrix protein, an unbranched polysaccharide, and an elastic protein; andwherein the thermogel comprises a gelatinous material and a cross-linking enzyme in an amount sufficient to result in gelation of the thermogel at a temperature from about 35° C. to 37° C.2. The biosealant of claim 1 , wherein the first extracellular matrix protein is collagen claim 1 , wherein the elastic protein is elastin claim 1 , and wherein the unbranched polysaccharide is sulfated glycosaminoglycan.3. The biosealant of claim 1 , wherein the cross-linking enzyme is transglutaminase.4. The biosealant of claim 1 , wherein the extracellular matrix hydrogel also comprises additional therapeutics including cells claim 1 , microsomes claim 1 , peptides claim 1 , or drugs.5. The biosealant of claim 1 , wherein the cross-linking enzyme is present in an amount from about 0.5 units/mL to 5 units/mL.6. The biosealant of claim 1 , wherein the gelatinous material is gelatin.7. The biosealant of claim 1 , wherein the thermogel comprises pores of diameter of about 0.025 mm to 90 mm.8. The biosealant of claim 1 , wherein the biosealant composition does not contain fibrin.9. The biosealant of claim 1 , wherein the first extracellular matrix protein is present in an amount from about 25% by weight to about 75% by weight of the total weight of the first extracellular matrix protein claim 1 , unbranched polysaccharide claim 1 , and elastic protein of the extracellular matrix hydrogel.10. The biosealant of claim 1 , wherein the unbranched polysaccharide is present in an amount from about 0.5% by weight to about 15% by weight of the total weight of the first extracellular matrix protein claim 1 , ...

BIOADHESIVE FOR OCCLUDING VESSELS

Bioadhesives and crosslinked gels therefrom are disclosed. The bioadhesives can be applied to a vessel for occluding the vessel. The present disclosure also describes kits that comprise the various components for preparing and applying the bioadhesives. Bioadhesives of the present disclosure include: (i) a biopolymer having one or more first chemically reactive amine groups; (ii) a biocompatible crosslinker having at least two second chemically reactive groups that can chemically react with the one or more first chemically reactive amine groups of the biopolymer; and (iii) a biocompatible rheological modifier. 1: A method of treating a vascular malformation of a mammal , the method comprising:injecting a bioadhesive into a vascular malformation of a mammal to displace blood in the malformation and prevent blood flow back into the malformation and to crosslink the bioadhesive in the malformation to form an occlusion in the malformation,wherein the bioadhesive comprises: (i) a biopolymer having one or more first chemically reactive amine groups; (ii) a biocompatible crosslinker having at least two second chemically reactive groups that can chemically react with the one or more first chemically reactive amine groups of the biopolymer; and (iii) a biocompatible rheological modifier, andwherein the biopolymer and crosslinker form a crosslinked network and the biocompatible rheological modifier does not substantially react with the biopolymer or the biocompatible crosslinker.2: The method of wherein the biocompatible rheological modifier has a viscosity sufficient to displace fluid within the malformation while the biopolymer and biocompatible crosslinker crosslink.3: The method of comprising injecting the bioadhesive into the malformation by a syringe.4: The method of further comprising preparing the bioadhesive by combining the biopolymer claim 1 , the biocompatible crosslinker and the biocompatible rheological modifier prior to injecting the bioadhesive into the ...

SEALANT SYRINGE ASSEMBLY

The present invention relates to a sealant syringe assembly. An aspect of the present invention may provide a sealant syringe assembly comprising: a first syringe including a plurality of chambers and discharging a first solution which is a mixture of a buffer solution and compound powder; a reaction solution syringe including at least one chamber and discharging a reaction solution capable of reacting with the first solution; a base in which the first syringe and the reaction solution syringe are stably seated; and a connector for connecting the first syringe and the reaction solution syringe to mix and discharge the first solution and the reaction solution, wherein the first solution and the reaction solution react with each other to thus have a changed property such that a shear storage modulus exceeds a shear loss modulus, and the first syringe includes: three packing members provided inside the first syringe; a passage provided in the inner circumferential surface of the first syringe; and a plunger for providing a pressure to one of the packing members, wherein a buffer solution is provided to a chamber of one side provided between the three packing members, and compound powder is a provided to a chamber of the other side provided between the three packing members. 1. A sealant syringe assembly comprising:a first syringe for discharging a first solution;a reaction solution syringe for discharging a reaction solution capable of reacting with the first solution;a base on which the first syringe and the reaction solution syringe are seated; anda connector for connecting the first syringe and the reaction solution syringe to mix and discharge the first solution and the reaction solution,wherein the first solution reacts with the reaction solution to cause change in properties such that a shear storage modulus exceeds a shear loss modulus, three or more packing members provided inside the first syringe;', 'chambers defined by adjacent packing members of the three ...

HAEMOSTATIC COMPOSITION COMPRISING CRYSTALLINE POLYPHOSPHATE

The present invention relates to the use of polyphosphate in crystalline form for treatment of wounds, especially bleeding wounds, wherein the anion of the polyphosphate has a (numerical) average of at least 4 phosphorus atoms per polyphosphate anion. The invention additionally relates to a composition suitable for treatment of wounds, especially bleeding wounds, comprising an inventive polyphosphate and a carrier material. The invention further provides a method suitable for production of the inventive composition, which comprises the introduction of the polyphosphate and optionally further haemostatic agents into the carrier material, or into a component or into a precursor of the carrier material 1. A method for treating wounds , more particularly bleeding wounds , comprising applying a composition that comprises a polyphosphate in crystalline form , wherein an anion of the polyphosphate has on average (number average) at least 4 phosphorus atoms per polyphosphate anion.2. The method of claim 1 , wherein the polyphosphate has a degree of crystallinity claim 1 , determined by X-ray diffractometry claim 1 , of at least 90%.3. The method of claim 2 , wherein the anion of the polyphosphate is substantially linear.4. The method of claim 1 , wherein the polyphosphate anion has on average from 8 to 500 claim 1 , phosphorus atoms.5. The method of claim 1 , wherein cations of the polyphosphate are independently selected from Na claim 1 , K claim 1 , NH claim 1 , Ca claim 1 , Mg claim 1 , Zn claim 1 , Sn claim 1 , Fe and Al.6. The method of claim 5 , wherein the cations of the polyphosphate are selected from Na claim 5 , K claim 5 , NH and Ca.7. The method of claim 1 , wherein particles of the crystalline polyphosphate have a weight-average particle size within the range of 1 μm to 1 mm.8. A composition comprising a crystalline polyphosphate and a carrier material claim 1 , wherein an anion of the crystalline polyphosphate has an average (number average) at least 4 ...

METHOD AND APPARATUS TO CONTROL THE HETEROGENEOUS FLOW OF BONE CEMENT AND IMPROVE OSSEOINTEGRATION OF CEMENTED IMPLANT

The present invention provides processes for combined applications of making grooves on an implant surface, applying MgO nanoparticles with PMMA cement, restricting the cement movement by PCL nanofiber and tethering biomolecules with PCL nanofiber to enhance mechanical stability and osseointegration of PMMA cement with bone. This is achieved through enhanced osteoconductive properties, roughness, and less viable fracture originating sites at the bone-cement interface. Such combined applications of nanoparticle and nanofiber on the mechanical stability and osseointegration of cemented implant is heretofore unknown, but as provided by the present invention can solve the debonding problem of cemented implant from bone. 115-. (canceled)16. An electrospun nanofiber (ENF) membrane , comprising:a fiber matrix exhibiting a tubular shape having an inside span and an outside span, said matrix formed by electrospinning nanofibers on to an elongated substrate rotated around a longitudinal axis during electrospinning to produce said tubular shape;multiple layers of nanofibers, each of said layers consisting of generally aligned fiber strands and said fiber strands comprising each layer are collectively positioned at an oblique angle to the fiber strands in each adjacent layer to form said matrix.17. The electrospun nanofiber (ENF) membrane of claim 16 , further comprising up to 30 layers of nanofibers claim 16 , and preferably no more than 24 layers of nanofibers.18. The electrospun nanofiber (ENF) membrane of claim 16 , further comprising nanoparticle additives (NPA) immobilized with poly-ε-caprolactone (PCL) nanofiber.19. The electrospun nanofiber (ENF) membrane of claim 16 , further comprising growth factors immobilized collagen-poly-ε-caprolactone nanofiber matrix (CG-PCL NFM).20. The electrospun nanofiber (ENF) membrane of claim 16 , further comprising fibronectin (FN) and magnesium oxide nanoparticles (MgO NPs) immobilized CG-PCL NFM.21. The electrospun nanofiber (ENF) ...

BIOCOMPATIBLE PHASE INVERTIBLE PROTEINACEOUS COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications. 1. A method of sealing a surgical site comprising: (a1) a liquid proteinaceous substrate with', '(a2) a preformed liquid crosslinking composition comprising a macromolecular crosslinking agent which comprises a reaction product of an excess of a liquid aldehyde crosslinking agent and a glycosaminoglycan,, '(a) mixing'}thereby forming a phase invertible composition; and(b) applying the phase invertible composition to a surgical site of a patient in need thereof to seal the surgical site.2. The method of claim 1 , wherein the glycosaminoglycan is hyaluronan.3. The method of claim 1 , wherein liquid proteinaceous substrate comprises a proteinaceous material selected from the group consisting of: albumin claim 1 , elastin claim 1 , fibrin and soluble and insoluble forms of collagen and combinations thereof.4. The method of claim 1 , wherein the proteinaceous substrate further comprises a tackifying agent.5. The method of claim 1 , wherein the proteinaceous substrate further comprises a plasticizer.6. The method of claim 1 , wherein the proteinaceous substrate further comprises a carbohydrate.7. The method of claim 1 , wherein the crosslinking agent comprises glutaraldehyde.8. The method of claim 7 , wherein the glutaraldehyde is heat stabilized.9. The method of claim 1 , wherein liquid proteinaceous substrate comprises albumin.10. The method of claim 1 , wherein the macromolecular crosslinking agent comprises at least one reactive moiety that can ...

CORE BIOPSY NEEDLE

The invention relates to a core biopsy needle () for obtaining a tissue sample comprising a hollow outer needle () extending along a longitudinal axis (L), and an inner needle (), which is at least partially arranged or arrangeable within said outer needle along said longitudinal axis (L), wherein said inner needle () comprises at least one tissue-holding surface (), wherein said tissue-holding surface () is adapted such that a tissue () adheres to the at least one tissue-holding surface (), when the core biopsy needle () is inserted into the tissue (). 2110. The core biopsy needle () according to claim 1 , characterized in that said outer needle () comprises a maximum extension (e) of less than 1.2 mm claim 1 , particularly less than 1 mm claim 1 , transversely to said longitudinal axis (L).312140. The core biopsy needle () according to claim 1 , characterized in that said at least one tissue-holding surface () comprises a plurality of protrusions () claim 1 , each having a length (y) extending along said longitudinal axis (L) claim 1 , a width (x) extending in a circumferential direction in respect of said longitudinal axis (L) claim 1 , and a height (z) extending in a radial direction in respect of said longitudinal axis (L).414040. The core biopsy needle () according to claim 3 , characterized in that the ratio between said width (x) and said length (y) of said protrusions () or the ratio between said length (y) and said width (x) of said protrusions () is at least 2 to 1.5140. The core biopsy needle () according to claim 3 , characterized in that the ratio between said height (z) and said width (x) and/or the ratio between said height (z) and said length (y) of said protrusions () is at least 1 to 1.61. The core biopsy needle () according to claim 3 , characterized in that said height (z) is 1 μm to 100 μm claim 3 , particularly 10 μm to 80 μm claim 3 , more particularly 24 μm to 40 μm.71. The core biopsy needle () according to claim 3 , characterized in that ...

ADHESIVE BIOPOLYMERS AND USES THEREOF

Provided herein are polymers having the general formula I as defined herein, 23-. (canceled)4. The polymer of claim 1 , wherein at least one of R-Ris hydrogen.5. (canceled)6. The polymer of claim 1 , wherein said biopolymer is selected from the group consisting of a polypeptide and a polysaccharide.7. The polymer of claim 6 , wherein said polypeptide comprises at least one resilin amino acid sequence.810-. (canceled)11. The polymer of claim 1 , being substantially devoid of crosslinking by said dihydroxyphenyl moiety.12. The polymer of claim 1 , wherein said dihydroxyphenyl moiety and said linking moiety form a part of a DOPA residue.13. The polymer of claim 1 , wherein said dihydroxyphenyl moiety and said linking moiety do not form a part of a DOPA residue.1417-. (canceled)18. The polymer of claim 1 , comprising a plurality of said dihydroxyphenyl moiety.19. (canceled)20. The polymer of claim 18 , being characterized by a ratio of molecular weight to dihydroxyphenyl moieties in a range of from 1.5 KDa per dihydroxyphenyl moiety to 12 KDa per dihydroxyphenyl moiety.21. (canceled)22. The polymer of claim 18 , being a polypeptide wherein a percentage of amino acid residues of said polypeptide which comprise said dihydroxyphenyl moiety is in a range of from 0.5% to 5%.2324-. (canceled)25. The polymer of claim 1 , exhibiting an adhesiveness to a surface claim 1 , said adhesiveness being characterized by resistance to stress of 1 KPa in a direction perpendicular to said surface.26. A method of preparing the polymer of claim 13 , wherein said linking moiety is attached to said biopolymer via a covalent bond formed between a reactive group in said linking moiety and a functional group on said biopolymer claim 13 , the method comprising:a) providing a compound comprising said dihydroxyphenyl moiety and said reactive group; andb) contacting said compound with a biopolymer comprising at least one of said functional group to form said covalent bond,thereby preparing the ...

VASCULAR EMBOLIC SYSTEM

Systems and methods of blocking a biological vessel are provided. The systems and methods may comprise introducing to the vessel an amphiphilic peptide. The peptide may comprise at least thirteen amino acids that may alternate between a hydrophobic amino acid and a hydrophilic amino acid. The peptide may form a beta-sheet spontaneously in an aqueous solution in the presence of a cation. 1. A method of blocking a biological vessel in a subject comprising:introducing a catheter into a biological vessel;positioning an end of the catheter in a target area of the biological vessel in which at least a partial obstruction is desired;administering through the catheter a solution comprising an amphiphilic peptide comprising at least 12 amino acids that alternate between a hydrophobic amino acid and a hydrophilic amino acid in an effective amount and in an effective concentration to form a hydrogel under physiological conditions to allow at least partial blockage of the biological vessel;removing the catheter from the biological vessel with the at least partial obstruction in place.2. The method of claim 1 , wherein the peptide solution comprises a contrast agent.3. The method of claim 2 , further comprising visualizing a region comprising at least a portion of the biological vessel.4. The method of claim 3 , wherein visualizing the region comprising at least a portion of the biological vessel comprises visualizing the region during at least one of:identifying the target area of the biological vessel;introducing the catheter;positioning the end of the catheter in the target area;administering the solution;removing the catheter; andvisualizing the biological vessel after removing the catheter.5. The method of claim 4 , wherein visualizing the region comprises imaging using X-ray radiography.6. The method of claim 3 , wherein visualizing the region provides for selective administration of the solution to the biological vessel.7. The method of claim 3 , further comprising ...

Spray-dried thrombin and methods of using and making spray-dried thrombin

Spray-dried thrombin materials obtained from feedstock solutions comprising less than 5% by weight albumin and excluding trehalose or other excipients as well as methods of manufacturing the thrombin materials and methods of treating bleeding wounds are disclosed. The methods of use include applying reconstituted spray-dried thrombin topically to a bleeding site, optionally in conjunction with gelatin.

MINERALIZED TISSUE ADHESIVE/FILLER COMPOSITION COMPRISING CROSSLINKED OSTEOPONTIN

The present disclosure concerns a mineralized tissue adhesive or filler composition comprising an intermolecular crosslinked osteopontin protein for treating an exposed surface of a mineralized tissue. The mineralized tissue adhesive or filler composition can be added directly on the exposed surface of the mineralized tissue or on a layer of monodisperse OPN protein which has been deposited on the exposed surface of the mineralized tissue. The present disclosure also includes methods and kits of using the mineralized tissue adhesive or filler composition especially in dental applications. The present application also provides dental coatings, fillings, bondings and veneers comprising the mineralized tissue adhesive or filler composition described herein. 1. A method of treating an exposed surface of a mineralized tissue , the method comprising contacting a mineralized tissue adhesive or filler composition having intermolecular crosslinked osteopontin (OPN) protein directly with (i) the exposed surface or (ii) a first layer of monodisperse OPN protein directly deposited on the exposed surface so as to treat the exposed surface.2. The method of claim 1 , wherein the exposed surface comprises at least one crack and the method further comprises filing the at least one crack.3. The method of claim 1 , further comprising contacting the mineralized tissue adhesive or filler composition directly with (i) a second surface or (ii) a second layer of monodisperse OPN protein directly deposited on the second surface so as to adhere the first surface to the second surface.4. The method of claim 3 , wherein the second surface is a mineralized tissue.5. The method of claim 3 , wherein the second surface is an artificial surface.6. The method of claim 1 , further comprising depositing monodisperse OPN protein on the exposed surface to form the first layer of monodisperse OPN protein.7. The method of claim 1 , further comprising providing the mineralized tissue adhesive or filler ...

Hemostatic Powders with Self-Assembling Peptide Hydrogels

Hemostatic powders are synergistically used in conjunction with self-assembling peptide hydrogels to promote hemostasis at a target site. Related methods, kits, and devices for hemostasis are disclosed. 1. A kit for hemostasis , comprising:a solution comprising a self-assembling peptide comprising between about 7 amino acids and 32 amino acids in an effective amount and in an effective concentration for use in forming a hydrogel under physiological conditions to promote hemostasis; anda hemostatic powder miscible in the solution to form a mixture capable of promoting hemostasis on a wound having an initial bleeding score of 2 or higher, as assessed on the World Health Organization (WHO) Bleeding Scale.2. The kit of claim 1 , wherein the mixture is capable of promoting hemostasis on a wound having an initial bleeding score of 3 or higher claim 1 , as assessed on the World Health Organization (WHO) Bleeding Scale.3. The kit of claim 1 , wherein the self-assembling peptide is selected from the group consisting of RADA16 and IEIK13.4. The kit of claim 1 , wherein the self-assembling peptide comprises KLD12.5. The kit of claim 1 , wherein the hemostatic powder comprise microspheres and/or micro-fibrils.6. The kit of claim 1 , wherein the hemostatic powder comprises a bio-absorbable material.7. The kit of claim 6 , wherein the hemostatic powder comprises collagen claim 6 , gelatin claim 6 , chitosan claim 6 , polysaccharide claim 6 , starch claim 6 , hyaluronic acid claim 6 , silk fibroin claim 6 , or oxidized regenerated cellulose.8. The kit of claim 1 , wherein the hemostatic powder comprises a synthetic biomaterial.9. The kit of claim 8 , wherein the synthetic biomaterial is selected from the group consisting of: Poly(lactide-co-glycolide) (PLGA) claim 8 , (PLGA)-poly(ethylene glycol)-block-copolymer claim 8 , and (PLGA-b-PEG).10. The kit of claim 1 , further comprising a syringe system for mixing the solution and the hemostatic powder.11. The kit of claim 1 , further ...

BIOLOGICAL GLUE AND USE THEREOF AS A MEDICAMENT

Disclosed is a thrombin-free, liquid biological glue for therapeutic use, including fibrinogen and factor VIIa. The ratio of fibrinogen concentration to FVIIa concentration is 20000:1 to 1000:1, with the concentrations being expressed in weight per volume. The fibrinogen concentration is lower than 60 mg/ml. Also disclosed are a kit for preparing such a biological glue, a method to prepare the glue, and a medicament. 126-. (canceled)27. Thrombin-free , liquid biological glue for therapeutic use , comprising fibrinogen and factor VIIa , wherein the ratio of fibrinogen concentration to FVIIa concentration is 20000:1 to 1000:1 , with the concentrations being expressed in weight per volume , and wherein the fibrinogen concentration is lower than 60 mg/ml.28. The biological glue according to claim 27 , having a fibrinogen content of 0.1 mg to 45 mg per ml of biological glue.29. The biological glue according to claim 27 , having a FVIIa content of 0.1 μg to 10 μg per ml of biological glue.30. The biological glue according to claim 27 , comprising a source of calcium ions.31. The biological glue according to claim 30 , comprising 2 μmoles to 30 μmoles of the calcium ion source per ml of biological glue.32. The biological glue according to claim 27 , further comprising at least one gelling agent.33. A therapeutic method comprising administering a thrombin-free claim 27 , liquid biological glue comprising fibrinogen claim 27 , factor VIIa and at least one gelling agent.34. The therapeutic method according to claim 33 , wherein the biological glue has a fibrinogen content lower than 60 mg/ml.35. The therapeutic method according to claim 33 , wherein the biological glue has a FVIIa content of 0.1 μg to 10 μg per ml of biological glue.36. The therapeutic method according to wherein the biological glue comprises a source of calcium ions.37. The biological glue according to claim 32 , wherein said at least one gelling agent is a cellulose derivative.38. The biological glue ...

Biodegradable medical adhesive or sealant composition

The present invention provides a biodegradable medical adhesive or a sealant composition containing an oxidized glycosaminoglycan and a polyamine. The composition of the present invention exhibits improved effects in biodegradation, coating property, gelation time, hemostatic capacity, adhesive force, moisture absorptive capacity and the like, and thus can be applied to various medical uses in which a medical adhesive or sealant can be used, such as biotissue adhesion, filling, coating, adhesion prevention, wound covering, leakage prevention and hemostasis.

BIOCOMPATIBLE PHASE INVERTIBLE PROTEINACEOUS COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications. 1. A phase invertible formulation comprising:a. a first composition comprising a proteinaceous substrate composition; andb. a second composition comprising a crosslinking composition comprising an aldehyde and a glycosaminoglycan.2. The phase invertible formulation of claim 1 , wherein the proteinaceous substrate comprises a proteinaceous material selected from the group consisting of: albumin claim 1 , elastin claim 1 , fibrin and soluble and insoluble forms of collagen and combinations thereof.3. The phase invertible formulation of claim 1 , wherein the proteinaceous substrate comprises albumin.4. The phase invertible formulation of claim 1 , wherein the aldehyde is glutaraldehyde.5. The phase invertible formulation of claim 4 , wherein the glutaraldehyde is heat-treated.6. The phase invertible formulation of claim 1 , wherein the glycosaminoglycan is hyaluronic acid.7. A phase invertible formulation comprising:a. a first composition comprising a proteinaceous substrate composition having about 30%-50% albumin, and about 0.1%-0.3% chitosan chloride; andb. a second composition comprising a crosslinking composition having about 3%-10% glutaraldehyde, about 0.1%-1% hyaluronic acid.8. The phase invertible formulation of claim 7 , wherein the phase invertible formulation further comprises about 0%-1.5% sodium salt of carboxymethylcellulose to increase viscosity of the formulation.9. The phase invertible formulation of claim 8 , wherein the glutaraldehyde ...

USE OF SELF-ASSEMBLING POLYPEPTIDES AS TISSUE ADHESIVES

The present invention relates to a self-assembling polypeptide for use as tissue adhesive. The present invention also relates to the use of a self-assembling polypeptide as tissue adhesive. Further, the invention is directed to the use of a self-assembling polypeptide to glue one or more cosmetic compounds on skin, mucosa, and/or hair. Furthermore, the invention is directed to a self-assembling polypeptide for use in gluing one or more pharmaceutical compounds on tissue, skin, mucosa, and/or hair.

TISSUE SEALANT COMPOSITIONS, VASCULAR CLOSURE DEVICES, AND USES THEREOF

The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures. 119.-. (canceled)20. A vascular closure device comprising:a plug for at least partially occluding an opening in a vasculature tissue; andan optical dye covalently bound to, or noncovalently associated with, the plug, wherein the optical dye exhibits a first optical condition when the plug is in a first state prior to occluding the opening in the vasculature tissue and exhibits a second optical condition that is distinguishable from the first optical condition when the plug is in a second state upon at least partially occluding the opening in the vasculature tissue.21. The closure device of claim 20 , wherein at least partial occluding of the opening in the vasculature tissue initiates a coagulation cascade in a subject.22. The closure device of claim 20 , wherein occluding the opening in the vasculature tissue results in formation of a tissue seal claim 20 , a fibrin network claim 20 , a synthetic polymer network or a clot.23. The closure device of claim 22 , wherein occluding the opening in the vasculature tissue incorporates ...

DUAL SYRINGE CARTRIDGE AND HOUSING

A dispensing device and cartridge for simultaneous delivery and mixing of multiple co-reactive materials, the cartridge having proximal and distal ends, and having an elongated holder body with substantially parallel longitudinal voids. Multiple syringe bodies are disposed parallel within the voids and multiple co-reactive materials are separately disposed in the syringe bodies. The dispensing device also includes a longitudinal housing which is structured and arranged to receive the cartridge. 1. A cartridge for storage and delivery of multiple co-reactive materials comprising:an elongated holder body having substantially parallel longitudinal voids;multiple hollow cylindrical bodies disposed substantially parallel within said longitudinal voids;said co-reactive materials separately disposed in said multiple hollow cylindrical bodies,wherein the multiple hollow cylindrical bodies have open proximal ends, nozzles at distal ends thereof, and pistons positioned inside, said pistons sealing the open proximal end and slidably moveable within the hollow cylindrical bodies and having no plungers attached.2. The cartridge of claim 1 , further comprising removable closure caps sealing the nozzles.3. The cartridge of claim 1 , further comprising a removable rear closure cap having plugs fitting into the open proximal ends of said multiple claim 1 , substantially parallel hollow cylindrical bodies.4. The cartridge of claim 1 , wherein the open proximal ends have diameters substantially the same as inner diameters of the hollow cylindrical bodies claim 1 , and the nozzles have Luer tapers.5. The cartridge of claim 1 , wherein the hollow cylindrical bodies are glass syringe bodies.6. The cartridge of claim 1 , wherein said co-reactive materials are fibrinogen and thrombin.7. The cartridge of claim 1 , wherein the holder body comprises windows into each of the substantially parallel longitudinal voids.8. The cartridge of claim 1 , wherein the holder body comprises a longitudinal ...

Procoagulant Peptides and Their Derivatives and Uses Therefor

The present invention is directed to a hemostatic or tissue sealing material having (a) a peptide having a sequence SEQ ID NO: 1 or an amino acid analog sequence thereof, and (b) a scaffold for said peptide or amino acid analogue sequence. The scaffold is preferably hemostatic, such as a natural or genetically engineered absorbable polymer, a synthetic absorbable polymer, or combinations thereof. The natural or genetically engineered absorbable polymers can be selected from the group consisting of a protein, a polysaccharide, or combinations thereof.

Methods And Compositions For Medical Articles Produced From Proteinaceous Compounds

The invention disclosed herein provides compositions and methods for biocompatible biomaterials with improved control of microorganisms, improved biocompatibility, lower toxicity, and reduce vCJD transmission potential. These combined benefits cascade to provide improved efficacy, improved patient compliance and improved performance, while limiting clinical complications in treatment.

PEPTIDE HYDROGEL PROPERTIES AND ITS APPLICATIONS

Peptide hydrogels having a self-assembling, 3-dimensional nanofiber matrix are described. The nanofiber matrix comprises an amphiphilic peptide and optionally albumin. The peptide comprises (consists of) a terminal hydrophobic region, a central turning region, and a terminal hydrophilic region. Methods of making such hydrogels are also described, along with methods of using the hydrogels as scaffolding for tissue engineering, hemostatic agents, as well as 3-dimensional cell cultures, and for drug delivery, encapsulation of active agents (therapeutic cells, molecules, drugs, compounds), cell transplantation, cell storage, virus culture and storage. 1. A method of storing and expanding cells , said method comprisingmixing cells with a self-assembling amphiphilic peptide and a hydrogelation agent, wherein said peptide consists of a terminal hydrophobic region, a central turning region, and a terminal hydrophilic region, to yield a 3-dimensional cell culture comprising said cells embedded in a hydrogel matrix, said hydrogel matrix comprising a 3-dimensional nanofiber matrix comprising said peptide; andmaintaining said cells in said hydrogel matrix under cell culture conditions.2. The method of claim 1 , wherein said hydrogelation agent is a source of albumin or metal ion.3. The method of claim 2 , wherein said source of albumin is serum-supplemented cell media comprising said cells.4. The method of claim 2 , wherein said metal ion is calcium.5. The method of claim 1 , wherein said maintaining comprises covering said hydrogel matrix with cell media and incubating said hydrogel containing said cells under said cell culture conditions6. The method of claim 1 , wherein said cells are stem cells or red blood cells.7. The method of claim 6 , wherein said cells are stem cells claim 6 , further comprising expanding said cells in said hydrogel matrix for at least about 20 passages after said mixing claim 6 , wherein said stem cells remain in an undifferentiated state.8. The ...

PLEURAL AIR LEAK TEST SYSTEM

Disclosed are methods, apparatus, and systems useful for detecting leaks in pleural tissue. Also disclosed are methods of detecting and sealing such leaks. Indicator dye or stain is aerosolized and delivered to the lung via anesthetic equipment, oxygen tube, endoscope, or other suitable equipment, the dye is allowed to travel through the lung along the path or paths of least resistance emerging at the surface of the lung, staining the tissue indicative of a leak. Some embodiments include introducing one part of a two part sealant with the dye, and applying the second part of the sealant to the stain identified leak locations. 1. A method of identifying and sealing an air leak in lung tissue in a patient in need thereof , the method comprising:introducing a first composition comprising an indicator and a first component of a multi-part sealant into the lung via an aerosol or nebulizer,allowing the first composition to accumulate at one or more air leak,applying a second composition comprising a second component of a multi-part sealant externally to the lung at locations where the indicator has accumulated, andallowing the first component and the second component of the multi-part sealant to cure with one another to form a pleural sealant.2. The method of claim 1 , wherein the first composition is introduced to the patient in need thereof via the breathing apparatus.3. A method of identifying and sealing an air leak in lung tissue in a patient in need thereof claim 1 , the method comprising:introducing an indicator compound into the lung via an aerosol or nebulizer,allowing the indicator compound to accumulate at one or more air leak,applying a suture or sealant at a location identified by accumulated indicator compound.4. A pressurized canister for facilitating identification of pleural air leaks claim 1 , the pressurized canister comprising:a canister capable of holding a pressurized fluid;a pressurized fluid comprising one or more indicator compounds.5. A pleural ...

Silk-Based Adhesives

In some embodiments, the present invention provides compositions including silk fibroin, at least one hydrophilic agent, and at least one catechol donating agent, wherein the at least one hydrophilic agent and at least one catechol donating agent are conjugated to the silk fibroin. According to various embodiments, at least a portion of the silk fibroin may be crosslinked. In some embodiments, the silk fibroin is at least 50% (e.g., 60%, 70%, 80%, 90%, 95% or more) crosslinked. In some embodiments, the present invention also provides methods for making such compositions.

Dual syringe cartridge and housing

A dispensing device and cartridge for simultaneous delivery and mixing of multiple co-reactive materials, the cartridge having proximal and distal ends, and having an elongated holder body with substantially parallel longitudinal voids. Multiple syringe bodies are disposed parallel within the voids and multiple co-reactive materials are separately disposed in the syringe bodies. The dispensing device also includes a longitudinal housing which is structured and arranged to receive the cartridge and has a malleable spray or mixing tip for accessing difficult to reach locations.

NOVEL POLYPEPTIDES AND MEDICAL USES THEREOF

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition. 1. A polypeptide comprising an amino acid sequence selected from the group consisting of:(a) SEQ ID NO: 5 derived from the α3 chain of collagen type VI,(b) a fragment of SEQ ID NO: 5, wherein the fragment of SEQ ID NO: 5 comprises at least 20 contiguous amino acids of SEQ ID NO: 5, and(c) a variant of SEQ ID NO: 5, wherein the variant comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 5,wherein the polypeptide is between 20 and 200 amino acids in length, andwherein the polypeptide, fragment, or variant is capable of killing or attenuating the growth of microorganisms.2. A polypeptide according to wherein the microorganisms are selected from the group consisting of bacteria claim 1 , mycoplasmas claim 1 , yeasts claim 1 , fungi and viruses.3. A polypeptide according to claim 1 , wherein the polypeptide is capable of:(a) binding to the membrane of the microorganism,(b) causing membrane disruption of the microorganisms,(c) promoting wound closure,(d) exhibiting an antimicrobial effect greater than or equal to that of LL-37, and/or(e) exerting an anti-endotoxic effect.46-. (canceled)7. A polypeptide ...

SELF-ASSEMBLING PEPTIDE COMPOSITIONS

The present disclosure provides peptide compositions (e.g., of self-assembling peptides) with particular attributes (e.g., peptide identity, peptide concentration, pH, ionic strength [including salt identity and/or concentration), etc that show particularly useful material properties. The present disclosure also provides technologies for selecting and/or formulating particular peptide compositions useful in specific contexts. In some embodiments, provided peptide compositions have an elevated pH within the range of about 2.5 to about 3.5 and/or an ionic strength that is above that of a corresponding composition of the same peptide, at the same concentration, in water, but is below a critical salt point for the peptide (e.g., so that the composition is not cloudy). 1. An IEIK13 composition comprising:an IEIK13 peptide at a concentration of at least 0.25%;which composition has a pH within the range of about 2.5 to about 4.0.2. The composition of claim 1 , which composition is a solution.3. The composition of claim 1 , which composition is a gel.4. The composition of claim 1 , wherein the composition has ionic strength within the range of about 0.0001 M to about 0.1 M.5. The composition of claim 4 , wherein the ionic strength is adjusted/given by common salts claim 4 , wherein the common salts are selected from the group consisting of NaCl claim 4 , KCl claim 4 , MgCl claim 4 , CaCl claim 4 , and CaSO.6. The composition of claim 4 , wherein the ionic strength is given by common salts claim 4 , wherein the common salts are composed of one or more salt forming cations and one or more salt forming anions claim 4 , wherein the salt forming cations are selected from the group consisting of ammonium claim 4 , calcium claim 4 , iron claim 4 , magnesium claim 4 , potassium claim 4 , pyridinium claim 4 , quaternary ammonium claim 4 , and sodium claim 4 , wherein the salt forming anions are selected from the group consisting of acetate claim 4 , carbonate claim 4 , chloride ...

Film forming polymeric sealant for medical use

The invention provides a polymeric film-forming medical sealant. The medical sealant is useful for application to the tonsils and adenoids, wherein the sealant performs at least one of the following functions, a) inhibit the colonization of bacteria, b) inhibit the binding of bacteria to tissue, c) reduction of tissue morbidity, d) hemostasis, e) coating and protection of tissue during healing. e) promotion of healing, and f) reduction of pain.

一种皮肤创口粘合修复材料及其制备方法、应用

本发明属于皮肤创口敷料技术领域，具体涉及一种皮肤创口粘合修复材料及其制备方法；其中，粘合修复材料以天然蛋白质为主体材料，蛋白质分别与氨基类多糖和二价金属离子发生化学和物理双交联；其中，蛋白质与氨基类多糖发生酰胺化反应从而发生化学交联，蛋白质与二价金属离子发生物理络合，从而形成交联结构。另外，本发明的粘合修复材料的含水量的变化能够使得粘合修复材料的粘合性能发生改变。本发明的粘合修复材料在物体的粘结、密封和皮肤的创口粘合具有广阔的应用前景。

Surgical method using purified amphipathic peptide composition

Biodegradable medical adhesive or sealant compositions

본 발명은 산화 글리코사미노글리칸과 폴리아민을 포함하는 생분해성 의료용 접착제 또는 실란트 조성물을 제공한다. 본 발명의 조성물은 생분해성, 도포성, 겔화 시간, 지혈능, 접착력 및 수분 흡수력 등에서 개선된 효과를 나타내어, 생체 조직의 접착, 충전, 도포, 유착 방지, 창상 피복, 누출방지 및 지혈 등의 다양한 의료 용도로 활용될 수 있다. The present invention provides a biodegradable medical adhesive or sealant composition comprising glycosaminoglycans and polyamines. The composition of the present invention exhibits improved effects in terms of biodegradability, coatability, gelation time, hemostatic function, adhesive force and water absorption ability and is useful for various purposes such as adhesion, filling, application, adhesion prevention, wound coating, It can be used for medical purposes.

Biocompatible phase invertible proteinaceous compositions

生体適合性のある転相可能なタンパク質の組成物

One component fibrin glue comprising a polymerization inhibitor

本文提供了包含纤维蛋白单体和可逆纤维蛋白聚合阻断剂的稳定液体封闭剂制剂、制剂的制备和使用方法。

Circulation-overlapping solid-phase preparation with covering being out of immobilized binding preparation

FIELD: medicine. SUBSTANCE: the present innovation deals with methods and compositions for targeted supply of circulation -overlapping solid-phase thrombocytes-binding preparations for treating vascularized tumor or hyperplastic tissue. The solid-phase preparation covered except polystyrene with thrombocytes-binding preparation, such as Willebrand's factor, should be purposefully directed towards vascular net-target in vivo, where it binds and activates thrombocytes which, in their turn, bind and activate other thrombocytes. Variant of composition for inducing thrombogenesis in vivo and containing a solid-phase thrombocytes-binding preparation, except polystyrene, could be consisted of the first binding component and the second binding component, where the first binding component has got binding area for binding a solid-phase preparation with a ligand-receptor complex, and not with a ligand or receptor separately, as for the second binding component it has got binding area for thrombocytes. The innovation provides rapid formation of a dense thrombus that leads to overlapping the circulation in the desired area due to thrombocytic fixation towards the surface of a solid-phase preparation along with increasing its sizes and developing a multi-layer structure of activated thrombocytes as a dense matrix. EFFECT: higher efficiency. 29 cl, 12 ex, 2 tbl ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß (19) RU (11) 2 295 329 (13) C2 (51) ÌÏÊ A61K A61K A61K A61K A61K ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ A61P ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ,A61L ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ (12) 9/00 (2006.01) 9/16 (2006.01) 38/36 (2006.01) 38/39 (2006.01) 47/48 (2006.01) 35/00 (2006.01) 31/16 (2006.01) ÎÏÈÑÀÍÈÅ ÈÇÎÁÐÅÒÅÍÈß Ê ÏÀÒÅÍÒÓ (21), (22) Çà âêà: 2004110935/14, 11.09.2002 (30) Êîíâåíöèîííûé ïðèîðèòåò: 12.09.2001 (ïï.1-29) US 60/318,339 (73) Ïàòåíòîîáëàäàòåëü(è): ÂèÐåêñ Ìåäèêàë Êîðïîðåéøí (CA) (43) Äàòà ïóáëèêàöèè çà âêè: 10.03.2005 R U (24) Äàòà íà÷àëà îòñ÷åòà ñðîêà äåéñòâè ïàòåíòà: 11.09.2002 (72) Àâòîð(û): ÑÒÅÂÀÐÒ Ìè÷åë Â. ( ...

Injectable fibrin composition for bone augmentation

The present invention relates to a biodegradable injectable composition for bone augmentation comprising fibrin, a contrast agent and calcium salt-containing particles, as well as a method for bone augmentation in a patient suffering from a bone disorder comprising injecting said composition into a non-mineralized or hollow portion of said bone.

Hemostatic compositions and methods for their preparation

FIELD: medicine. SUBSTANCE: group of inventions relates to agents and materials for stimulating hemostasis and sealing tissue. A method for forming a powdered hemostatic composition is disclosed, including stages, at which suspension of a mixture containing particles of fibrinogen, thrombin, and fibers of oxidized regenerated cellulose (hereinafter – ORC) is formed in a non-aqueous solvent with a low boiling temperature, providing evaporation of the solvent under environmental conditions; suspension is sprayed through a nozzle onto substrate; the non-aqueous solvent is waited to evaporate; the composition is separated from substrate, the composition is sieved and thus a powdered hemostatic composition is formed. A powdered hemostatic composition containing at least partially integrated agglomerated ORC fibers, fibrinogen and thrombin, and a method for the treatment of a wound by using this powdered hemostatic composition are also disclosed. EFFECT: group of inventions provides hemostatic material that has high uniformity, integrity, high adhesion strength and quickly forms gel/clot. 18 cl, 9 dwg, 4 tbl, 8 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 756 891 C2 (51) МПК A61L 24/08 (2006.01) A61K 38/36 (2006.01) A61P 7/04 (2006.01) A61K 31/717 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61L 24/08 (2021.05); A61L 2430/00 (2021.05); A61K 38/363 (2021.05); A61K 31/717 (2021.05); A61P 7/04 (2021.05) (21)(22) Заявка: 2019107165, 10.08.2017 10.08.2017 Дата регистрации: 06.10.2021 15.08.2016 CN 201610666290.2; 07.09.2016 US 15/258,549 (43) Дата публикации заявки: 15.09.2020 Бюл. № 26 (45) Опубликовано: 06.10.2021 Бюл. № 28 (56) Список документов, цитированных в отчете о поиске: CN 104721878 A, 24.06.2015. US 20040265371 A1, 30.12.2004. US 20150017225 A1, 15.01.2015. RU 2235539 C1, 10.09.2004. C 2 C 2 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 15.03.2019 (86) Заявка PCT: IB 2017/054884 (10.08. ...

Patent RU2019107165A3

ВИ“? 2019107165” АЗ Дата публикации: 14.12.2020 Форма № 18 ИЗ,ПМ-2011 Федеральная служба по интеллектуальной собственности Федеральное государственное бюджетное учреждение 5 «Федеральный институт промышленной собственности» (ФИПС) ОТЧЕТ О ПОИСКЕ 1. . ИДЕНТИФИКАЦИЯ ЗАЯВКИ Регистрационный номер Дата подачи 2019107165/04(013782) 10.08.2017 РСТЛВ2017/054884 10.08.2017 Приоритет установлен по дате: [ ] подачи заявки [ ] поступления дополнительных материалов от к ранее поданной заявке № [ ] приоритета по первоначальной заявке № из которой данная заявка выделена [ ] подачи первоначальной заявки № из которой данная заявка выделена [ ] подачи ранее поданной заявки № [Х] подачи первой(ых) заявки(ок) в государстве-участнике Парижской конвенции (31) Номер первой(ых) заявки(ок) (32) Дата подачи первой(ых) заявки(ок) (33) Код страны 1. 201610666290.2 15.08.2016 СМ 2. 15/258,549 07.09.2016 05 Название изобретения (полезной модели): [Х] - как заявлено; [ ] - уточненное (см. Примечания) ГЕМОСТАТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ Заявитель: ГУАНЧЖОУ БАЙОСИЛ БАИЙОТЕК КО., ЛТД., СМ, ЭТИКОН, ИНК., 0$ 2. ЕДИНСТВО ИЗОБРЕТЕНИЯ [Х] соблюдено [ ] не соблюдено. Пояснения: см. Примечания 3. ФОРМУЛА ИЗОБРЕТЕНИЯ: [Х] приняты во внимание все пункты (см. п см. Примечания [ ] приняты во внимание следующие пункты: [ ] принята во внимание измененная формула изобретения (см. Примечания) 4. КЛАССИФИКАЦИЯ ОБЪЕКТА ИЗОБРЕТЕНИЯ (ПОЛЕЗНОЙ МОДЕЛИ) (Указываются индексы МПК и индикатор текущей версии) Аб. 24/08 (2006.01) Аб/1К 38/36 (2006.01) Аб1Р 7/04 (2006.01) Аб/1К 31/717 (2006.01) 5. ОБЛАСТЬ ПОИСКА 5.1 Проверенный минимум документации РСТ (указывается индексами МПК) Аб 11. 24/08, Аб1К 38/36, Аб11, 24/00, Аб1Р 7/04, Аб1К 31/717 5.2 Другая проверенная документация в той мере, в какой она включена в поисковые подборки: 5.3 Электронные базы данных, использованные при поиске (название базы, и если, возможно, поисковые термины): Е-Глбгагу, Езрасепее, боозе, боозе Раеп$, боозе эспо]аг, Раеагсв, РиИБСВет, ...

Self-propelled particle for obtaining self-propelled foaming tissue sealant and preparation method thereof

本发明公开了一种用于获得自推式发泡组织密封胶的自推进颗粒，该自推进颗粒由组分A和组分B组成；组分A为吸附或包埋生物活性剂的载体；组分B为质子化固体酸。本发明还同时提供了上述自推进颗粒的制备方法。本发明改变了现有组织密封胶只局限于可及的出血部位和打开手术出血，从而具有更广的应用范围和更好的止血效果。

Rapid photocuring bio-glue with adhesion, heamostatic and wound healing efficacy

본 발명은, 누에 고치 유래 천연 단백질 고분자인 실크 피브로인의 대량 생산성, 생분해성, 창상 재생 기능, 생체 접착 기능, 뛰어난 생체 적합성 및 생물학적 위험성이 없다는 장점을 이용하여 이를 주성분으로한 광경화성 바이오글루를 제조함으로써, 실크 피브로인의 우수한 접착 강도와 생체 적합성, 지혈 및 창상 치유 능력이 동등 이상으로 유지되면서 출혈 및 창상 봉합이 필요한 부위에 적용할 수 있는 급속 광경화 바이오글루 및 이의 제조방법을 특징으로 한다. The present invention uses the advantages of mass productivity, biodegradability, wound regeneration function, bioadhesion function, excellent biocompatibility, and no biohazard of silk fibroin, a natural protein polymer derived from cocoon, to prepare a photocurable bioglue containing the same. By doing so, it features a rapid photo-curing bioglu that can be applied to areas requiring bleeding and wound closure while maintaining excellent adhesion strength, biocompatibility, hemostasis and wound healing ability of silk fibroin at equal or higher levels, and a manufacturing method thereof.

Hemostatic sponge and preparation method thereof

本发明公开了一种止血海绵及其制备方法。止血海绵由三层组成：内层为凝血酶涂层；中间层由胶原蛋白、海藻酸钠和抗菌肽通过交联剂谷氨酰胺转氨酶交联后，与负载有凝血酶的壳聚糖微球混合，再通过两步冷冻干燥制得，外层为由聚己内酯、壳聚糖、凝血酶和柞蚕丝素蛋白构成的静电纺丝层；其中中间层中胶原蛋白、海藻酸钠、含凝血酶的壳聚糖微球和抗菌肽的质量比为(30‑40)：(60‑70)：(30‑50)：(3‑5)；外层中聚己内酯、壳聚糖、凝血酶和柞蚕丝素蛋白的质量比为(40‑50)：(30‑40)：(3‑5)：(10‑30)。通过上述方式，本发明的止血海绵具有良好的生物相容性、抗菌性能和止血性能。

Injectable fibrin composition for bone augmentation

本发明涉及一种生物可降解的用于骨质增加的可注射组合物，其包含纤维蛋白、造影剂和含有钙盐的颗粒。本发明还涉及一种用于在患有骨疾病的病人体内骨质增加的方法，包含将所述组合物注入所述骨质的未矿化部分或空心部分。

Vascular occlusion solid-phase agent with immobilized platelet binding agent

본 발명은 일반적으로, 고형상 혈소판 의존성 혈관 폐색 제제를 표적화하고 전달하기 위한 방법 및 조성물에 관한 것이다. 특히, 혈소판 결합제로 코팅된 입자 또는 코일 또는 스텐트는 고형 종양 매쓰 또는 AV-기형 또는 동맥류 또는 내피 누출의 혈관계와 같은 혈관계를 표적하도록 지시되고 이어서 고형상 제제는 혈소판과 결합하고 이를 활성화시키고 이어서 혈소판은 또 다른 혈소판과 결합하고 이를 활성화시킨다. 이러한 과정은 고형상 제제에 대해 혈소판 매개 혈전을 신속하게 형성시켜 혈관 폐색을 일으킨다. The present invention generally relates to methods and compositions for targeting and delivering solid platelet dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binders are directed to target a vascular system such as a solid tumor mass or an AV-deformation or an aneurysm or an vascular system of endothelial leakage, and then the solid preparation binds to and activates platelets. It binds to and activates another platelet. This process rapidly forms platelet-mediated thrombi for solid preparations, causing vascular occlusion. 혈소판, 고형상 제제, 고형 종양, 혈관 폐색, 폰 빌레브란트 인자 Platelets, solid preparations, solid tumors, vascular occlusion, von Willebrand factor

Biodegradable medical adhesive or sealant composition

本发明提供包含氧化糖胺聚糖和聚胺的生物降解性医疗用粘结剂或密封剂组合物。本发明的组合物在生物降解性、涂敷性、凝胶化时间，止血功能、粘结力及水分吸收力等方面呈现改善的效果，从而可用于生物组织的粘结、填充、涂敷、防止粘连、伤口覆盖、防止露出及止血等可使用医疗用粘结剂或密封剂的多种医疗用途。

A kind of preparation method of fibroin-small peptide blood coagulation microballoon

本发明公开了一种丝素‑短肽凝血微球的制备方法。由丝素和短肽复合而成，短肽为RGD、TI或者LD；将蚕茧脱胶后形成的纤维状丝素溶解获得丝素蛋白溶液；将丝素蛋白溶液与短肽混匀，注入无水乙醇自组装再超声冷冻，取出后使融化为乳白色溶液，经第一次离心后倒去上清液得到丝素蛋白颗粒，再经第二次离心后用去离子水洗涤两次，两次离心后超声第三次离心，弃去底部沉淀从而得到丝素蛋白微球悬浮液，超声后立刻冷冻；取出冷冻好的悬浮液，冷冻干燥所得丝素短肽微球粉末。本发明获得的产物具有优良的生物相容性，用途广泛，同时能配制溶液注射使用以及治疗体内脏器出血的凝血和外部创伤的凝血，环保无污染。

Composition for tissue welding and method of use

A composition for tissue welding is provided. The composition comprises an active compound, a solvent, and an energy converter and is insoluble in physiological fluids. A method for welding a tissue is also provided. The method comprises contacting a tissue with the above composition and exciting the composition such that the tissue becomes welded.

Hemostatic compositions

발명은 지혈에 사용하기 적합한 입상 형태의 가교된 젤라틴을 포함하는 지혈 조성물을 공개하며, 여기서 조성물은 15.0 내지 19.5 % (w/w), 바람직하게는 16.0 내지 19.5 % (w/w), 16.5 내지 19.5 % (w/w), 17.0 내지 18.5 % (w/w) 또는 17.5 내지 18.5 % (w/w), 보다 바람직하게는 16.5 내지 19.0 % (w/w) 또는 16.8 내지 17.8 % (w/w), 특히 바람직하게는 16.5 내지 17.5 % (w/w)을 함유한 페이스트 형태로 존재하며, 여기서 조성물은 압출 개선제를 포함한다.

Silk fibroin and polyethylene glycol-based biomaterials

This invention relates to methods and compositions for preparation of silk-PEGs based biomaterials through crosslinking by chemically reacting active polyethylene glycols (PEGs) possessing different chemical groups (e.g., thiols and maleimides functionalized PEGs) that are additionally stabilized by the beta-sheet formation of silk fibroin. The crosslinked silk-PEGs biomaterials present strong adhesive properties, which are comparable to or better than the current leading PEG-based sealant, depending on the silk concentration in the silk-PEGs biomaterials. In addition, the silk-PEGs based biomaterials are cytocompatible, show decreased swelling behavior and longer degradation times, which make them suitable for hemostatic applications where the current available tissue sealant products can be contraindicated.

Methods of and apparatus for treating vascular defects

A method of and apparatus for treating vascular defects. A catheter having a selectively energizeable coil on its distal end. The catheter is particularly adapted for the delivery of magnetic embolic materials. The coil can be energized to aid in the magnetic navigation of the catheter, to help retain magnetic material in the catheter, to draw ejected magnetic material back into the catheter. A catheter can also be used to deliver a magnetic patch that can be magnetically applied to a vascular defect such as an aneurysm.

Thrombin isolated from blood and blood fractions

Methods, apparatus, and compositions related to generating and using thrombin. Methods include preparing a solution comprising thrombin by precipitating fibrinogen from a liquid comprising whole blood or a blood fraction. Precipitated fibrinogen is removed from the liquid to form a post-precipitation liquid that is incubated with calcium and a plurality of beads to form a clot. A solution comprising thrombin is separated from the clot. Thrombin prepared thereby can be used as a tissue sealant and in methods of applying a tissue sealant to subject, including application of an autologous tissue sealant.

Functionalized surgical adhesives

A bioadherent composition includes a first mixture containing a plurality of reactive members of a specific binding pair, said reactive members being bound to a ligand capable of binding a receptor on biological tissue, and a second mixture containing a plurality of complementary reactive members of the specific binding pair, said complementary reactive members being bound to a ligand capable of binding a receptor on biological tissue, said reactive members capable of forming covalent bonds with said complementary reactive members via a reaction selected from Huisgen cycloaddition reactions, Diels-Alder reactions, and/or thiol-alkene reactions. A method for bonding biological tissue involves utilizing the bioadherent composition.